Relationship of clinical factors with adiponectin and leptin in children with newly diagnosed type 1 diabetes by Gu, Yuan
RELATIONSHIP OF CLINICAL FACTORS WITH ADIPONECTIN AND LEPTIN IN 
CHILDREN WITH NEWLY DIAGNOSED TYPE 1 DIABETES  
by 
Yuan Gu 
BE, Nanjing Institute of Technology, China, 2006 
ME, University of Shanghai for Science and Technology, China, 2009 
Submitted to the Graduate Faculty of 
the Department of Biostatistics  
Graduate School of Public Health in partial fulfillment 
of the requirements for the degree of 
Master of Science 
University of Pittsburgh 
2015 
ii 
UNIVERSITY OF PITTSBURGH 
GRADUATE SCHOOL OF PUBLIC HEALTH 
This thesis was presented 
by 
Yuan Gu 
It was defended on 
June 17, 2015 
and approved by 
Ingrid M. Libman, MD, PhD 
Assistant Professor, Pediatrics Children’s Hospital, University of Pittsburgh Medical Center 
Francis Pike, PhD,  
Assistant Professor, Critical Care Medicine, School of Medicine, University of Pittsburgh 
Evelyn O. Talbott, DrPH, MPH  
Professor, Epidemiology, Graduate School of Public Health, University of Pittsburgh 
Thesis Advisor: Vincent C. Arena, PhD 
Associate Professor, Biostatistics, Graduate School of Public Health, University of Pittsburgh 
 iii 
Copyright © by Yuan Gu 
2015 
iv 
ABSTRACT  
Aim: To investigate potential predictors for adiponectin, leptin, and adiponectin/leptin ratio in 
children with newly diagnosed type 1 diabetes (T1D).  
Methods: Medical records were reviewed from 175 subjects (165 Caucasian, 8 African 
American (AA), 59.4% male, mean age 9.7 ± 3.8 yrs) with new onset T1D diabetes diagnosed 
between January 2004 and December 2006 at Children’s Hospital of Pittsburgh of UPMC. 
Adiponectin, leptin,  islet cell autoantibodies including ICA, glutamic acid decarboxylase (GAD) 
(65 kDa isoform), insulin antibody (IA2), insulin autoantibody (IAA) and zinc transporter 8 
(ZnT8A), anthropometric and clinical variables  including systolic and diastolic blood pressure, 
height, weight, waist circumference (with calculation of body mass index (BMI), waist percentile 
and waist/height ratio) and insulin dose, laboratory data including hemoglobin A1c(HbA1c), 
glucose, lipid profile (low-density lipoprotein (LDL) and high-density lipoprotein (HDL), 
cholesterol, and triglycerides) and C-peptide were all measured at 3 months after start of insulin 
therapy. HLA typing was determined for the presence of the DQ2 and/or DQ8 haplotypes.  
Results: Univariate and multivariate linear regression analyses were performed assessing factors 
related with adiponectin and leptin, using two different procedures. Nine candidate models were 
identified and examined for consistency. Adiponectin was significantly associated with age, 
waist percentile and greater number of positive antibodies. Leptin was significantly associated 
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with gender, BMI z-score, central obesity, C-peptide, GAD, HbA1c, and insulin dose adjusted by 
HbA1c. Adiponectin/leptin ratio was significantly associated with gender, age waist percentile, 
waist/height ratio, insulin dose adjusted by HbA1c, HbA1c, glucose, and C-peptide.      
Public health focused conclusion: Adiponectin, leptin and adiponectin/leptin ratio had different 
significant predictors. However there were a set of factors that where in common. Insulin 
resistance has been recognized to be present in youth with T1D. Adiponectin and leptin have an 
influence on insulin sensitivity. Identifying the significant predictors for these hormones may 
contribute to our understanding of their role in the pathogenesis of T1D. The identification of 
potential modifiable risk factors in children with this condition would be high priority.  
vi 
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1.0  INTRODUCTION 
Type 1diabetes (T1D) is the most common form of diabetes mellitus in children and 
young adults. Although there has been substantial progress in the knowledge of the pathogenesis 
and natural history of T1D in recent years, there is no effective treatment available to cure the 
disease [1,2] .Worldwide, the incidence of T1D continues to increase at a rate of nearly 3% per 
year [3]. In 2011, an estimated 490,100 children, worldwide, below the age of 15 years were 
living with T1D [4]. 
The obesity epidemic is widely blamed for a startling rise in the incidence of type 2 
diabetes (T2D) among children. Intriguing new research suggests it may also play a role for the 
increase in T1D [5]. A marked increase in the prevalence of overweight and obesity in type T1D 
has been demonstrated [6]. 
Insulin resistance may play a role in the pathogenesis of T1D [7]. Adiponectin and leptin 
are hormones secreted by the adipose tissue and have an influence on insulin sensitivity [8]. 
Adiponectin levels are low in human obesity, cardiovascular disease, and T2D. Paradoxically, 
high adiponectin levels, specifically the high molecular weight isoform, have been reported in 
established T1D. Leptin, the adipocytokine product of the Ob(Lep) gene, reflects the degree of 
adiposity and is stimulated by insulin, rising acutely with insulin therapy in both in vitro rodent 
studies and in children with new onset T1D. The adiponectin/leptin ratio also has been used in 
studies of T1D and T2D as a surrogate measure of insulin sensitivity [9].   
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Previous studies have explored racial differences in adiponectin and leptin and their 
relationship with islet autoimmunity in equally matched children of African American (AA) and 
Caucasian with new onset T1D. Adiponectin levels increase as early as three days after initiation 
of insulin therapy with a statistically significant increase by day 5. No significant racial 
differences in adiponectin, leptin, and adiponectin/leptin ratio levels were found after adjustment 
for BMI. Subjects with higher number of positive autoantibodies had higher adiponectin levels, 
lower leptin levels, and higher adiponectin/leptin ratios than those with lower numbers of 
positive antibodies [9].   
This study aimed to evaluate adiponectin and leptin measured 3 months after diagnosis of 
T1D and their relationships with number of islet-cell autoantibodies and measures of adiposity.  
3 
2.0  METHODS 
2.1 DATA PREPARATION 
Two data sets were combined to form the data file used for this analysis. Subjects 
included were 351 children diagnosed with T1D from January 2004 to December 2006 at the 
Children’s Hospital of Pittsburgh of UPMC. Inclusion criteria was as follows: 1) informed 
consent signed, 2) diagnosis of diabetes requiring insulin, 3) insulin treatment at time of hospital 
discharge, and 4) available research laboratory results for three or more  β-cell autoantibodies, 
including islet cell autoantibodies (ICA), glutamic acid decarboxylase (GAD) (65 kDa isoform), 
insulin antibody (IA2), and insulin autoantibody (IAA). Cases with clinical maturity-onset 
diabetes of the young, T2D, and without AA were excluded. Of the 351 subjects recruited, 295 
met the inclusion criteria of 3 or more AA measured [10]. 
Of these 295 patients, 175 patients had measurements of adiponectin and leptin and were 
included in the analysis.  
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2.2 INDEPENDENT VARIABLES  
2.2.1 Demographic variables 
2.2.1.1 Age and gender 
Age and gender were considered as potential predictors or confounders of adiponectin, 
leptin and adiponectin/leptin ratio. 
2.2.1.2 Measure of Adiposity 
Body Mass Index (BMI), BMI percentile (BMI %), BMI z-score, height, weight 
BMI was defined as weight/height2 (kg/m2). Height (cm) and weight (kg) were collected 
to calculate BMI. Instead of using fixed BMI values to classify individuals (as typically done 
with adults), children’s BMI was classified using thresholds that vary to take into account the 
child’s age and gender. 
BMI thresholds were defined in terms of a specific BMI z-score, or BMI percentile (BMI 
%), on a child growth reference [11].  
Waist, Waist/height Ratio, Central Obesity 
The waist circumference (cm) and waist/height ratio were two indicators of obesity 
among young children [12]. Waist/height ratio had been proposed as an easily measurable 
anthropometric index for detection of central obesity [13]. Central obesity was defined as having 
a ratio exceeding 0.5. Waist circumference was the actual recording of circumference in 
centimeters. In addition, waist percentile (waist %) was available and is standardized to age and 
sex specific norms for children.  
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2.2.2 Measure of autoimmunity 
Initially, four types of antibodies including insulin antoantibodies(IAA,) insulin 
antibody(IA2), islet cell antibodies(ICA), and glutamic acid decarboxylase(GAD) (65 kDa 
isoform) were measured.  The appearance of autoantibodies to one or several of the autoantigens 
signaled an underlying autoimmune process [14]. Each antibody was classified as having a 
positive or negative response in the analysis. Additionally, a composite variable for the number 
of positive antibodies among IAA, ICA, IA2 and GAD was created.  
In addition, information was available for a fifth autoantibody , Zinc transporter 
8(ZnT8A) Studies following the T1D progression from the prodrome stage to onset among high 
risk patients found that the emergence of ZnT8A autoantibody usually preceded the appearance 
of T1D clinical symptoms and persisted to disease onset [15]. 
2.2.3 Clinical and laboratory measures 
Blood pressure was assessed and percentiles were determined based on gender, age and 
height. Laboratory measures included HbA1c and glucose. HbA1c measured glycated 
hemoglobin and indicated the average blood sugar levels in the past two to three months.  
Lipids including LDL, HDL, cholesterol and triglycerides, C-peptide and insulin dose 
were measured. 
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2.2.4 DQ2/DQ8  
HLA typing was available for the presence of DQ2, DQ8, DQ2 /DQ8. These haplotypes 
are related to risk of diabetes and were also considered as potential confounders of adiponectin, 
leptin and the adiponectin/leptin ratio in this study.  
2.2.5 Derived variables 
Some new independent variables were created for investigating more specific statistical 
relationship between predictors and outcomes.  
2.2.5.1 Categorical groups for number of positive antibodies 
The values of number of positive antibodies ranged from 0 to 4.We examined the number 
of positive antibodies by using several different groupings.  
Class 1:  0 versus ≥1.  
               0 --- people who have 0 positive antibody; 
               ≥1 --- people who have more than 1 positive antibodies.  
Class 2:  0-1 versus ≥2.  
               0-1 --- people who have 0 or 1 positive antibody; 
               ≥2 --- people who have 2, 3 or 4 positive antibodies.  
Class 3: 0, 1, 2 versus ≥3.  
              0 --- people who have 0 positive antibody; 
              1--- people who have 1 positive antibody; 
              2 --- people who have 2 positive antibodies; 
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              ≥3 --- people who have 3 or 4 positive antibodies.  
2.2.5.2 Insulin dose adjusted by HbA1c 
Insulin dose adjusted by HbA1c =HbA1c (percentile) + [4 * insulin dose (units per 
kilogram per 24 h)] 
In previous studies, a negative association between stimulated C-peptide and HbA1c 
(regression coefficient -0.21, P < 0.001) and insulin dose (-0.94, P < 0.001) was shown. Insulin 
dose adjusted by HbA1c reflected residual β-cell function and had better stability compared with 
the conventional definitions [16]. 
2.2.5.3 Zinc transporter 8 autoantibodies classes ( +   and   - ) 
The ZnT8A variable was developed into two categories.  
When ZnT8A was greater than 0.02, then the class was defined as +, when ZnT8A was 
less than 0.02, the class was defined as - .  
2.2.5.4 Glucose categorical classes ( <120 and  >= 120) 
The glucose variable was dichotomized into two categories: greater than or equal to 120 
and less than 120.  
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2.3 STATISTICAL ANALYSIS 
All continuous variables of interest were described by means, standard deviations, 
number of missing, number of observations, medians and percentages. For all the categorical 
variables, proportion summaries were used. Log transformations of adiponectin, leptin and 
adiponectin/leptin ratio were created to normalize the distributions of the outcome variables. The 
log scale of the three outcome variables would be used as the dependent variables in the 
regression analysis. Correlations between different independent continuous variables were 
assessed using Pearson correlation coefficients. Univariate linear regression and multivariate 
linear regression analysis were performed to investigate potential predictors of adiponectin, 
leptin and adiponectin/leptin ratio separately.  
Analyses were performed using SAS 9.3.  All statistical hypothesis testing was conducted 
as two-sided tests, and with statistical significance p < 0.05.  
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3.0  RESULTS 
3.1 DEPENDENT VARIABLES SUMMARY 
Table 1. Statistical summary for dependent variables 
Variable Minimum Maximum Mean Median N N 
miss 
Std 
Dev 
Lower 
Quartile 
Upper 
Quartile 
Skewness 
Adiponectin(ug/ml) 2.0 54.40 13.53 12.10 175 0 7.41 8.60 16.90 1.69 
Leptin(ug/ml) 0.78 58.60 6.84 4.55 160 15 7.5 2.80 7.50 3.58 
Adiponectin/leptin ratio 0.11 28.25 3.98 2.65 160 15 4.37 1.49 4.77 2.90 
Log(adiponectin) 0.69 3.99 2.47 2.49 175 0 0.54 2.15 2.83 -0.32 
Log(leptin) -0.25 4.07 1.57 1.52 160 15 0.81 1.03 2.01 0.30 
Log (adiponectin/leptin) -2.23 3.34 0.94 0.97 160 15 0.96 0.4 1.56 -0.21 
 
As shown in Table 1, 15 observations were missing for leptin and adiponectin/leptin 
ratio. The range of adiponectin was from 2 to 54ug/ml, the range of leptin was from 0.78 to 
58.6ug/ml, and the ratio was from 0.11 to 28.25.  
All distributions of the three variables were right skewed (Figure 1). Using the log 
transformation, the skewness was reduced near to 0. Using the Kolmogorov-Smirnov test for 
normality (Table 2), all three transformed variables were normally distributed, with each p-value 
>0.15. In the regression analysis, the log transformed variables would be used as the outcome 
variables. 
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 Figure 1. Comparison histograms of adiponectin, leptin, adiponectin/leptin ratio, 
 log (adiponectin),log (leptin), log (adiponectin/leptin) and normal distribution 
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Table 2. Kolmogorov-Smirnov test for normality on dependent variables 
Variable P-value for Kolmogorov-Smirnov test 
Log(adiponectin) >0.150 
Log(leptin) >0.150 
log (adiponectin/leptin) >0.150 
3.2 INDEPENDENT VARIABLES SUMMARY 
3.2.1 Continuous independent variables 
Table 3. Statistical summary for continuous independent variables 
Variable Minimum Maximum Mean Median N N Miss Std Dev 
Lower 
Quartile 
Upper 
Quartile 
BMI % 16.64 99.67 74.04 78.35 169 6 20.32 60.27 90.39 
BMI z-score -0.97 2.71 0.82 0.78 169 6 0.77 0.26 1.3 
Waist/height 0.24 0.67 0.47 0.46 143 32 0.06 0.43 0.51 
Age(months) 17 230 116.62 117 175 0 45.73 80 150 
Height(cm) 82.55 183.3 138.85 140.3 171 4 22.7 123.9 155.8 
IAA 0 6.53 0.79 0.17 50 125 1.41 0.06 0.7 
ICA 0 160 14.61 20 175 0 13.97 5 20 
GAD -0.02 1.15 0.25 0.1 175 0 0.32 0.02 0.37 
IA2 -0.01 1.97 0.59 0.5 175 0 0.54 0 1.13 
HbA1c 5.4 9.6 7.35 7.3 164 11 0.81 6.8 7.9 
Cholesterol 80 293 156.02 156 167 8 29.16 137 172 
LDL 35 228 90.68 88 97 78 29.02 73 105 
HDL 20.8 85.9 49.08 48.6 167 8 11.44 40.7 56.6 
Triglyceride 38 299 122.25 113 167 8 55.19 79 149 
Diastolic 
blood 
pressure 
10.29 99.95 60.77 62.3 145 30 20.38 49.17 74.62 
12 
percentile 
Systolic 
blood 
pressure 
percentile 
1.47 99.98 66.45 73.34 145 30 26.47 47.71 89.14 
Glucose 37 409 157.48 136 163 12 75.18 100 202 
C-peptide 0.05 10.2 1.88 1.48 166 9 1.55 0.77 2.64 
Insulin dose 0.1 2.12 0.49 0.45 162 13 0.28 0.3 0.6 
ZnT8A -0.01 1.09 0.22 0.12 164 11 0.27 0.01 0.38 
Descriptive results for the continuous independent variables were provided in Table 3. 
The mean level of BMI percentile was 74% and the lower quartile was 60.3%, which 
indicated that the subjects in this study were heavier than typical child at their same age. Ages of 
the patients ranged from 17 to 230 months (1.4 to 19.2 yrs). The mean age was 116.7 months 
(9.7 yrs), close to the median age, which was 117 months (9.8 yrs). Waist/height ratios ranged 
from 0.24 to 0.67.The mean value was 0.47, close to the lower quartile value of 0.43, and the 
upper quartile value was 0.51. The waist/height ratios of most observations were between 0.43 
and 0.51, and did not indicate central obesity (waist/height ratio≥0.5).  
Values for the other variable values were all in expected ranges. There was an 
appreciable number of subjects missing IAA (n=125) and LDL (n=78) information which limited 
our ability to include these variables in further analysis. In the later analysis, the two variables 
would be excluded.   
3.2.2 Categorical variables 
For the categorical variables, the frequency and missing numbers were provided by 
PROC FREQ in SAS 9.3 (Table 4). Over half were males (59.4%) and 42 (29.4%) had central 
Table 3 Continued
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obesity participated in the study.  Over 90% of the subjects had at least one positive antibody.  
With respect to DQ2/DQ8 less than 20% of the subjects were in the low risk group of X. For 
waist percentile, only 15.9% of the subjects were considered having large waist circumferences. 
Table 4. Statistical summary for categorical independent variables 
Variables Values Frequency Percent Frequency Missing 
Gender 
Male 104 59.43 
0 
Female 71 40.57 
Central obesity 
No 101 70.63 
32 
Yes 42 29.37 
DQ2/DQ8 
X 33 18.86 
0 
DQ2 47 26.86 
DQ8 61 34.86 
DQ2/DQ8 34 19.43 
Waist % 
<25% 62 43.06 
31 25%-75% 59 40.97 
>75% 23 15.97 
Number of positive antibodies 
0 15 8.57 
0 
1 25 14.29 
2 58 33.14 
3 64 36.57 
4 13 7.43 
3.3 CORRELATIONS 
The Pearson correlation coefficients assessed the linear associations between different 
continuous variables. The correlation coefficient between log (adiponectin) and log (leptin) was -
14 
0.0096, with a p-value of 0.9, which indicated that log (adiponectin) and log (leptin) were not 
linearly associated. 
In the correlation matrix (Table 5 and Table 6), the red shaded values indicated 
correlations greater than 0.75 and the blue shade values were from 0.5 to 0.75. The two colors 
indicated that the variables were highly correlated. The cyan shaded values indicated moderate 
correlations from 0.25 to 0.5. Careful consideration as to which variables of the highly correlated 
factors should be used in the regression models. Groups of highly correlated variables were 
summarized in Table 7.  
Table 5. Pearson correlation coefficients for continuous independent variables 
BMI % BMI z-score Waist 
Waist/heig
ht Age 
Heig
ht IAA ICA 
GA
D IA2 
HbA
1c 
Cholester
ol 
BMI %*    1.00 0.96 0.50 0.63 0.00 0.07 -0.04 0.01 -0.19 -0.21 -0.03 -0.02 
<.0001 <.0001 <.0001 0.97 0.34 0.78 0.94 0.01 0.01 0.71 0.83 
BMI z-score 0.96 1.00 0.58 0.73 0.00 0.08 -0.05 -0.01 -0.18 -0.21 -0.02 0.01 
<.0001 <.0001 <.0001 1.00 0.27 0.73 0.89 0.02 0.01 0.84 0.94 
Waist  0.50 0.58 1.00 0.63 0.68 0.75 -0.20 -0.10 0.09 -0.17 -0.15 -0.15 
<.0001 <.0001 <.0001 <.0001 <.0001 0.21 0.21 0.29 0.04 0.08 0.07 
Waist/height 0.63 0.73 0.63 1.00 -0.04 -0.02 0.13 -0.01 -0.09 -0.15 0.00 0.01 
<.0001 <.0001 <.0001 0.63 0.85 0.42 0.93 0.29 0.07 0.96 0.94 
Age 0.00 0.00 0.68 -0.04 1.00 0.95 -0.31 -0.10 0.17 -0.08 -0.30 -0.17 
0.97 1.00 <.0001 0.63 <.0001 0.03 0.18 0.03 0.27 <.0001 0.03 
Height 0.07 0.08 0.75 -0.02 0.95 1.00 -0.33 -0.13 0.16 -0.07 -0.31 -0.22 
0.34 0.27 <.0001 0.85 <.0001 0.02 0.10 0.04 0.39 <.0001 0.01 
IAA -0.04 -0.05 -0.20 0.13 -0.31 -0.33 1.00 0.13 -0.01 0.23 -0.02 -0.07 
0.78 0.73 0.21 0.42 0.03 0.02 0.39 0.97 0.11 0.88 0.62 
ICA 0.01 -0.01 -0.10 -0.01 -0.10 -0.13 0.13 1.00 0.11 0.31 0.07 -0.02 
0.94 0.89 0.21 0.93 0.18 0.10 0.39 0.16 <.0001 0.35 0.83 
GAD -0.19 -0.18 0.09 -0.09 0.17 0.16 -0.01 0.11 1.00 0.09 0.06 -0.14 
0.01 0.02 0.29 0.29 0.03 0.04 0.97 0.16 0.23 0.42 0.08 
IA2 -0.21 -0.21 -0.17 -0.15 -0.08 -0.07 0.23 0.31 0.09 1.00 0.08 -0.04 
0.01 0.01 0.04 0.07 0.27 0.39 0.11 <.0001 0.23 0.34 0.65 
HbA1c -0.03 -0.02 -0.15 0.00 -0.30 -0.31 -0.02 0.07 0.06 0.08 1.00 0.11 
0.71 0.84 0.08 0.96 <.0001 <.0001 0.88 0.35 0.42 0.34 0.16 
Cholesterol -0.02 0.01 -0.15 0.01 -0.17 -0.22 -0.07 -0.02 -0.14 -0.04 0.11 1.00 
0.83 0.94 0.07 0.94 0.03 0.01 0.62 0.83 0.08 0.65 0.16 
LDL 0.17 0.18 0.14 0.25 0.04 -0.04 -0.19 -0.03 -0.11 -0.21 0.06 0.59 
0.10 0.08 0.21 0.03 0.68 0.70 0.28 0.76 0.26 0.04 0.55 <.0001 
HDL -0.24 -0.25 -0.28 -0.28 -0.15 -0.17 -0.13 0.00 -0.03 0.16 0.12 0.29 
<.0001 <.0001 <.0001 <.0001 0.05 0.03 0.37 0.99 0.72 0.04 0.14 <.0001 
Triglyceride 0.04 0.06 -0.03 0.11 -0.10 -0.12 0.20 0.05 -0.07 0.00 -0.05 0.16 
0.61 0.46 0.76 0.21 0.19 0.14 0.17 0.48 0.37 0.96 0.56 0.04 
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Percentile 
for diastolic 
blood 
pressure 
0.07 0.09 -0.25 0.23 -0.47 -0.50 0.19 0.02 -0.03 0.02 0.10 0.11 
0.42 0.29 0.01 0.01 <.0001 <.0001 0.22 0.80 0.76 0.80 0.22 0.18 
Percentile 
for systolic 
blood 
pressure 
0.17 0.24 0.03 0.35 -0.30 -0.28 -0.07 -0.03 -0.18 -0.05 -0.09 0.14 
0.04 0.00 0.71 <.0001 <.0001 <.0001 0.64 0.73 0.03 0.53 0.27 0.10 
Glucose -0.09 -0.10 -0.27 -0.10 -0.27 -0.26 0.13 0.08 0.05 0.21 0.31 0.03 
0.25 0.21 <.0001 0.25 <0.01 <0.01 0.39 0.31 0.53 0.01 <.0001 0.67 
Insulin dose 
adjusted by 
HbA1c 
0.08 0.08 0.10 0.12 -0.02 -0.07 -0.13 0.03 0.19 0.05 0.71 0.10 
0.31 0.31 0.26 0.18 0.79 0.38 0.40 0.69 0.02 0.56 <.0001 0.23 
C-peptide 0.11 0.09 0.22 0.00 0.29 0.34 0.11 0.04 0.01 -0.07 -0.31 -0.15 
0.15 0.25 0.01 0.96 <.0001 <.0001 0.45 0.63 0.91 0.34 <.0001 0.06 
Insulin Dose 0.12 0.11 0.20 0.15 0.18 0.11 -0.14 -0.01 0.16 0.02 0.27 0.07 
0.12 0.16 0.02 0.09 0.02 0.15 0.34 0.91 0.04 0.78 <0.05 0.38 
ZnT8A -0.15 -0.16 -0.01 -0.05 0.05 0.07 -0.25 0.29 0.15 0.39 0.08 -0.09 
0.06 0.04 0.90 0.60 0.53 0.38 0.08 <.0001 0.05 <.0001 0.31 0.25 
*The first line for each variables was the correlation coefficient, the second line is the p-value (Prob > |r| under H0: Rho=0). 
Table 6. Pearson correlation coefficients for continuous independent variables 
LDL HDL Triglyceride 
Percentile 
for diastolic 
blood 
presuure 
Percentile 
for systolic 
blood 
presuure 
Glucose 
Insulin 
dose 
adjusted 
by HbA1c 
C-
peptide 
Insulin 
dose ZnT8A 
BMI %* 0.17 -0.24 0.04 0.07 0.17 -0.09 0.08 0.11 0.12 -0.15 
0.10 0.00 0.61 0.42 0.04 0.25 0.31 0.15 0.12 0.06 
BMI z-score 0.18 -0.25 0.06 0.09 0.24 -0.10 0.08 0.09 0.11 -0.16 
0.08 <.0001 0.46 0.29 0.00 0.21 0.31 0.25 0.16 0.04 
Waist  0.14 -0.28 -0.03 -0.25 0.03 -0.27 0.10 0.22 0.20 -0.01 
0.21 <.0001 0.76 0.01 0.71 <.0001 0.26 0.01 0.02 0.90 
Waist/height 0.25 -0.28 0.11 0.23 0.35 -0.10 0.12 0.00 0.15 -0.05 
0.03 <.0001 0.21 0.01 <.0001 0.25 0.18 0.96 0.09 0.60 
Age 0.04 -0.15 -0.10 -0.47 -0.30 -0.27 -0.02 0.29 0.18 0.05 
0.68 0.05 0.19 <.0001 <.0001 <.0001 0.79 <.0001 0.02 0.53 
Height -0.04 -0.17 -0.12 -0.50 -0.28 -0.26 -0.07 0.34 0.11 0.07 
0.70 0.03 0.14 <.0001 <.0001 <.0001 0.38 <.0001 0.15 0.38 
IAA -0.19 -0.13 0.20 0.19 -0.07 0.13 -0.13 0.11 -0.14 -0.25 
0.28 0.37 0.17 0.22 0.64 0.39 0.40 0.45 0.34 0.08 
ICA -0.03 0.00 0.05 0.02 -0.03 0.08 0.03 0.04 -0.01 0.29 
0.76 0.99 0.48 0.80 0.73 0.31 0.69 0.63 0.91 <.0001 
GAD -0.11 -0.03 -0.07 -0.03 -0.18 0.05 0.19 0.01 0.16 0.15 
0.26 0.72 0.37 0.76 0.03 0.53 0.02 0.91 0.04 0.05 
IA2 -0.21 0.16 0.00 0.02 -0.05 0.21 0.05 -0.07 0.02 0.39 
0.04 0.04 0.96 0.80 0.53 0.01 0.56 0.34 0.78 <.0001 
HbA1c 0.06 0.12 -0.05 0.10 -0.09 0.31 0.71 -0.31 0.27 0.08 
0.55 0.14 0.56 0.22 0.27 <.0001 <.0001 <.0001 <.0001 0.31 
Cholesterol 0.59 0.29 0.16 0.11 0.14 0.03 0.10 -0.15 0.07 -0.09 
<.0001 <.0001 0.04 0.18 0.10 0.67 0.23 0.06 0.38 0.25 
LDL 1.00 0.01 0.02 0.12 0.07 -0.02 0.11 -0.02 0.11 -0.17 
0.93 0.82 0.31 0.56 0.83 0.31 0.84 0.28 0.10 
HDL 0.01 1.00 -0.30 -0.05 -0.01 0.00 -0.04 -0.13 -0.08 -0.01 
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0.93 <.0001 0.58 0.94 0.99 0.63 0.10 0.34 0.88 
Triglyceride 0.02 -0.30 1.00 0.12 0.15 0.06 0.04 0.06 0.08 -0.10 
0.82 <.0001 0.17 0.09 0.49 0.61 0.48 0.31 0.20 
Percentile for 
diastolic blood 
pressure 
0.12 -0.05 0.12 1.00 0.39 0.08 0.04 -0.13 -0.04 0.04 
0.31 0.58 0.17 <.0001 0.38 0.67 0.13 0.68 0.61 
Percentile for 
systolic blood 
pressure 
0.07 -0.01 0.15 0.39 1.00 -0.03 -0.01 -0.03 0.06 0.06 
0.56 0.94 0.09 <.0001 0.76 0.93 0.69 0.48 0.45 
Glucose -0.02 0.00 0.06 0.08 -0.03 1.00 0.03 -0.03 -0.14 0.11 
0.83 0.99 0.49 0.38 0.76 0.76 0.70 0.09 0.20 
Insulin dose 
adjusted by 
HbA1c 
0.11 -0.04 0.04 0.04 -0.01 0.03 1.00 -0.30 0.87 0.05 
0.31 0.63 0.61 0.67 0.93 0.76 <.0001 <.0001 0.52 
C-peptide -0.02 -0.13 0.06 -0.13 -0.03 -0.03 -0.30 1.00 -0.20 0.05 
0.84 0.10 0.48 0.13 0.69 0.70 <.0001 0.01 0.51 
Insulin dose 0.11 -0.08 0.08 -0.04 0.06 -0.14 0.87 -0.20 1.00 -0.01 
0.28 0.34 0.31 0.68 0.48 0.09 <.0001 0.01 0.94 
ZnT8A -0.17 -0.01 -0.10 0.04 0.06 0.11 0.05 0.05 -0.01 1.00 
0.10 0.88 0.20 0.61 0.45 0.20 0.52 0.51 0.94 
*The first line for each variables was the correlation coefficient, the second line is the p-value (Prob > |r| under H0: Rho=0). 
Table 7. Highly correlated groups among independent variables 
Highly correlated groups Variables 
Pearson Correlation 
Coefficients 
1: BMI %, BMI z-score, waist/height, waist 
BMI % & BMI z-score 0.96 
BMI % & waist/height 0.63 
BMI z-score & waist 0.58 
BMI z-score & waist/height 0.73 
2: Waist, waist/height, age, height 
Waist & waist/height 0.63 
Waist & age 0.68 
Age & height 0.95 
Height & waist 0.75 
3: LDL, cholesterol LDL & cholesterol 0.59 
4: Insulin dose adjusted by HbA1c, Insulin 
dose, HbA1c 
Insulin dose adjusted by HbA1c & 
HbA1c 
0.71 
Insulin dose adjusted by HbA1c & 
insulin dose 
0.87 
Table 6 Continued
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3.4 UNIVARIATE LINEAR REGRESSION WITH SIMPLE ADJUSTMENT 
3.4.1 Simple regression of log (adiponectin) 
 Table 8. Univariate regression and univariate regression with age adjustment of log (adiponectin) 
Independent Var β P-value Adjuste
d Var 
β P-value R2 Pr > F N of 
missing 
BMI %* -0.002 0.33 0.004 6 
BMI % -0.002 0.315 Age -0.0029 0.002 0.063 0.0045 6 
BMI z-score -0.07 0.185 0.01 6 
BMI z-score -0.072 0.173 Age -0.0029 0.0017 0.07 0.003 6 
Central obesity -0.13 0.18 0.013 32 
Central obesity -0.118 0.224 Age -0.0025 0.013 0.055 0.0185 32 
Waist -0.009 0.0045 0.054 29 
Waist -0.0075 0.085 Age -0.0007 0.58 0.057 0.0155 29 
Height -0.005 0.0057 0.044 4 
Height 0.0053 0.34 Age -0.005 0.056 0.065 0.0036 4 
Waist/height -1.3 0.06 0.025 32 
Waist/height -1.38 0.043 Age -0.0027 0.0078 0.073 0.005 32 
HbA1c 0.076 0.15 0.013 11 
HbA1c 0.032 0.56 Age -0.0026 0.0081 0.055 0.01 11 
Cholesterol 0.0006 0.7 0.0009 8 
Cholesterol -0.00007 0.96 Age -0.0024 0.011 0.0399 0.0355 8 
LDL -0.002 0.17 0.02 78 
LDL -0.003 0.19 Age -0.003 0.009 0.088 0.013 78 
HDL 0.004 0.23 0.008 8 
HDL 0.003 0.4 Age -0.0023 0.015 0.044 0.025 8 
DQ2/DQ8  0.8007 0.0058 0.8007 0 
X 0 0 
DQ2 0.081 0.512 
DQ2/DQ8 class 0.012 0.927 
DQ8 0.096 0.414 
DQ2/DQ8  0.9912 Age -0.0024 0.0056 0.0498 0.0679 0 
X 0 0 
DQ2 0.108 0.374 
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DQ2/DQ8 class 0.019 0.882 
DQ8 0.116 0.316 
Triglycerides -0.0001 0.89 0.0001 8 
Triglycerides -0.0003 0.68 Age -0.0024 0.0091 0.041 0.033 8 
Percentile for diastolic blood 
pressure 
0.0022 0.34 0.006 30 
Percentile for diastolic blood 
pressure 
-0.0004 0.87 Age -0.002 0.032 0.038 0.063 30 
Percentile for systolic blood 
pressure 
2.3 0.26 0.009 30 
Percentile for systolic blood 
pressure 
0.0008 0.64 Age -0.002 0.03 0.039 0.05 30 
*The shaded rows are univariate regression analysis without adjustment for age.
Table 8 provided the results of the univariate regression and univariate regression with 
age adjustment of log (adiponectin).  
P-value: The p-values indicated if the independent variable was significant for predicting 
the outcome variable. In the univariate regression analysis, only waist, height, and waist/height 
ratio were significant for predicting log (adiponectin). After adjusting for age, waist and height 
became non-significant. However, waist/height ratio was still significant. This change indicated 
that after accounting for the effect of age on adiponectin, waist and height no longer added to the 
model.   
β coefficients: The β coefficients of waist, height and waist/height ratio in univariate 
regression models were negative, indicating  a negative linear relationship between the three 
independent variables and log (adiponectin).    
R2: Although in the univariate analysis, waist, height and waist/height ratio were 
significant, the R2 were very small, demonstrating that the variation explained by those variables 
were very low, only between 4 to 8 percent. Even after age adjustment, the amount of variation 
explained remained small. 
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All β coefficients were small, close to zero. This was in part because the  univariate 
regression models only predicted small percentages of the variability of the dependent variable. 
Covariate adjustment variable: The p-values indicated that age was significant for 
predicting log (adiponectin). The β coefficients indicated that age had a negative linear 
relationship with log (adiponectin).  
Table 9. Univariate regression and univariate regression with BMI percentile adjustment of log (adiponectin) 
Independent Var β P-value Adjusted Var β P-value R2 Pr > F 
N of 
missing 
IA2 -0.01 0.89 0.0001 0 
IA2 -0.017 0.83 BMI % -0.002 0.32 0.006 0.61 6 
IAA 0.067 0.22 0.03 125 
IAA 0.068 0.21 BMI % -0.003 0.42 0.049 0.32 126 
ICA -0.001 0.73 0.0007 0 
ICA -0.001 0.73 BMI % -0.002 0.33 0.006 0.59 6 
GAD 0.024 0.86 0.0002 0 
GAD 0.027 0.84 BMI % -0.002 0.36 0.006 0.61 6 
ZnT8A -0.17 0.29 0.007 11 
ZnT8A -0.2 0.2 BMI % -0.003 0.19 0.018 0.232 17 
Zinc category (+  ,-) -0.12 0.23 0.01 34 
Zinc category (+  ,-) -0.13 0.21 BMI % -0.003 0.22 0.02 0.255 39 
Insulin dose -0.03 0.83 0.0003 13 
Insulin dose -0.03 0.825 BMI % -0.002 0.37 0.0059 0.63 17 
Number of positive 
antibodies 
0.1114 0.0430 0.1114 0 
0 0 0 
1 0.2215 0.206 
2 -0.02 0.893 
3 -0.114 0.458 
4 -0.129 0.526 
Number of positive 
antibodies 
0.2522 BMI % -0.0022 0.3004 0.0376 0.2772 0 
0 0 0 
1 0.142 0.439 
2 -0.042 0.788 
3 -0.142 0.375 
4 -0.163 0.43 
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Number of positive 
antibodies 
(continuous) 
-0.07860 0.0421 0.0237 0.0421 0 
Number of positive 
antibodies 
(continuous) 
-0.07640 0.0538 BMI % -0.00269 0.1933 0.0277 0.0968 
Number of positive 
antibodies 
class1(0,≥1) 
-0.029 0.843 0.0002 0 
Number of positive 
antibodies class1(0, 
≥1) 
-0.0644 0.6656 BMI % -0.0022 0.3015 0.0068 0.5688 0 
Number of positive 
antibodies   
class2(0-1, ≥2) 
-0.213773 0.0273 0.0278 0 
Number of positive 
antibodies   
class2(0-1, ≥2) 
-0.187670 0.0585 -0.00206 0.3115 0.0269 0.1038 0 
Number of positive 
antibodies  
class3(0,1,2, ≥3) 
0.0570 0.0429 0.0570 0 
0 0 0 
1 0.221 0.204 
2 -0.021 0.893 
≥3 -0.116 0.44 
Number of positive 
antibodies 
class3(0,1,2, ≥3) 
0.1472 BMI % -0.00226 0.2967 0.0375 0.1770 0 
0 0 0 
1 0.1417 0.438 
2 -0.042 0.787 
≥3 -0.145 0.352 
Table 9 provided the results for the univariate regression and univariate regression with 
BMI percentile adjustment of log (adiponectin).  
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P-value: In the univariate regression analysis, number of positive antibodies (continuous), 
number of positive antibodies class2 and number of positive antibodies class3 were significant 
for predicting log (adiponectin) with p-values of 0.042, 0.027 and 0.057. With the addition of 
BMI percentile to the model, the p-values for number of positive antibodies (continuous), 
number of positive antibodies class2 and class3 increased to 0.054, 0.058 and 0.147.  
β coefficients : The β coefficients for number of positive antibodies (continuous), number 
of positive antibodies class2 and class3 indicated the negative linear relationship with  
log(adiponectin) before and after BMI percentile adjustment. 
R2 : In the univariate analysis of number of positive antibodies (continuous), number of 
positive antibodies class2 and class3, the R2 values were very small, revealing the variation 
explained from those variables were very low, only from 2 to 5 percent. With the addition of 
BMI percentile to the models, the R2 were still very small. 
Covariate adjustment variable: BMI percentile was not significant for predicting the log 
(adiponectin). 
Table 10. Univariate regression with C-peptide, glucose of log (adiponectin) 
Independent Var1 β P-value Independent Var2 β P-value R2 Pr > F N of 
missing 
Glucose 0.00005 0.923 0.00006 12 
C-peptide  -0.005 0.83 0.0003 9 
C-peptide/glucose -2.74 0.41 0.0045 21 
C-peptide  -0.009 0.74 Glucose 0.0001 0.85 0.001 0.93 21 
C-peptide  -0.009 0.73 Glucose(<120, >=120) 0.0004 0.996 0.0007 0.94 21 
Table 10 provided the results for the univariate regression analysis when glucose and C-
peptide were treated as predictors of log (adiponectin).  
P-value: None of independent variables was significant. 
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3.4.2 Simple regression of log(leptin) 
Table 11. Univariate regression and univariate regression with age adjustment of log (leptin) 
Independent Var β P-value Adjusted 
Var 
β P-value R2 Pr > F N of 
missing 
BMI % 0.012 <.0001 0.095 20 
BMI % 0.012 <.0001 Age 0.0044 0.0015 0.153 <.0001 20 
BMI z-score 0.4 <.0001 0.14 20 
BMI z-score 0.4 <.0001 Age 0.0044 0.0011 0.197 <.0001 20 
Central obesity 0.64 <.0001 0.122 44 
Central obesity 0.63 <.0001 Age 0.00408 0.006   0.172 <.0001 44 
Waist 0.024 <.0001 0.15 41 
Waist 0.026 0.0003 Age -0.0009 0.66 0.152 <.0001 41 
Height 0.008 0.0037 0.053 18 
Height 0.003 0.742 Age 0.00278 0.525 0.056 0.0121 18 
Waist/height 3.977 0.0006 0.088 44 
Waist/height 4.272 0.0002 Age 0.0047 0.0016 0.156 <.0001 44 
HbA1c 0.053 0.5075 0.0029 23 
HbA1c 0.14 0.0882 Age 0.00497 0.0007 0.08 0.003 23 
Cholesterol -0.0004 0.8561 0.00022 21 
Cholesterol 0.00071 0.75 Age 0.00484 0.0009 0.07 0.004 21 
LDL 0.004 0.1849 0.019 85 
LDL 0.004 0.2351 Age 0.00641 0.0013 0.13 0.0023 85 
HDL -0.0017 0.7657 0.00059 21 
HDL 0.0013 0.8211 Age 0.00482 0.001 0.07 0.004 21 
DQ2/DQ8  0.8629 0.0047 15 
X 0 0 
DQ2 0.148 0.45 
DQ2/DQ8 class 0.05 0.813 
DQ8 0.123 0.5101 
DQ2/DQ8  0.9299 Age 0.0043 0.0023 0.0628 0.0386 15 
X 0 0 
DQ2 0.11 0.563 
DQ2/DQ8 class 0.0503 0.8050 
DQ8 0.1036 0.5688 
Triglycerides -0.000038 0.9755 0.000006 21 
Triglycerides 0.00036 0.76 Age 0.00481 0.0009 0.07 0.004 21 
Percentile for diastolic 0.00015 0.96 0.000016 41 
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blood pressure 
Percentile for diastolic 
blood pressure 
0.0049 0.1827 Age 0.0046 0.0051 0.058 0.0197 41 
Percentile for systolic 
blood pressure 
0.0015 0.553 0.0026 41 
Percentile for systolic 
blood pressure 
0.00388 0.1430 Age 0.0044 0.0051 0.06 0.016 41 
Table 11 provided the results for the univariate regression and univariate regression with 
age adjustment of log (leptin).  
P-value: In the univariate regression analysis, BMI percentile, BMI z-score, central 
obesity waist, height and waist/height ratios were significant for predicting log (leptin). When 
the covariate of age was added to the models, those variables were still significant except height, 
due to the high correlation between age and height.  
β coefficients: The β coefficients of BMI percentile, BMI z-score , central obesity, waist , 
height and waist/height ratios in univariate regression models were all positive, revealing the 
positive linear relationship with log (leptin).  
R2 : The R2  of the univariate regression models of BMI percentile, BMI z-score , central 
obesity , waist , height and waist/height ratios were very small, demonstrating that the variation 
explanation from those variables were very low, no more than 5 percent. After age was adjusted, 
the effect of predicting variation increased by nearly 10 percent, and ranged from 15 to 18 
percent.   
Covariate adjustment variable: Age was significant for predicting log (leptin). However, 
in the model of waist and height, age reduced its significant importance because of high 
correlations between age and height and age and waist.  Age had positive linear relationship with 
log (leptin), indicating that when age increased, log (leptin) also increased.  
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Other variables: When age was added as a covariate, it had an influence on the 
relationships between HbA1c and log (leptin), percentile for diastolic blood pressure and log 
(leptin) and percentile for systolic blood pressure and log (leptin). Although p-values became 
smaller, none reached statistical significance. 
Table 12. Univariate regression and univariate regression with BMI percentile adjustment of log (leptin) 
Independent Var β P-value Adjusted Var β P-value R2 Pr > F N of 
missing 
IA2 -0.135 0.25 0.0083 15 
IA2 -.0414 0.7251 BMI % 0.012 0.0002 0.095 0.0005 20 
IAA 0.059 0.4 0.014 125 
IAA 0.072 0.2727 BMI % 0.0147 0.0023 0.199 0.0061 126 
ICA -0.0056 0.21 0.0099 15 
ICA -0.0055 0.2 BMI % 0.012 <0.0001 0.1 0.0002 20 
GAD 0.152 0.47 0.0033 15 
GAD 0.39 0.064 BMI % 0.014 <0.0001 0.115 <0.0001 20 
ZnT8A -0.492 0.052 0.025 23 
ZnT8A -0.35 0.167 BMI % 0.012 0.0004 0.11 0.0002 28 
Zinc category (+  ,-) 0.0142 0.93 0.00006 44 
Zinc category (+  ,-) 0.123 0.43 BMI % 0.0153 <0.0001 0.122 0.0003 48 
Insulin dose 0.914 0.0001 0.099 27 
Insulin dose 0.782 0.0006 BMI % 0.0114 0.0003 0.176 <.0001 30 
Number of positive 
antibodies 
0.4085 0.0252 0.4085 15 
0 0 0 
1 0.08 0.772 
2 0.276 0.259 
3 -0.019 0.937 
4 0.053 0.8651 
Number of positive 
antibodies 
0.6659 BMI % 0.012201 0.0003 0.1090 0.0039 20 
0 0 0 
1 0.251 0.3705 
2 0.347 0.145 
3 0.2038 0.396 
4 0.22872 0.4529 
Number of positive -0.027 0.652 0.0013 15 
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antibodies (continuous) 
Number of positive 
antibodies (continuous) 
0.024 0.687 BMI % 0.0125 <0.0001 0.0957 0.0005 20 
Number of positive 
antibodies class1(0, ≥1) 
0.1075 0.6363 0.0014 0.6363 15 
Number of positive 
antibodies class1(0, ≥1) 0.274 0.2173 BMI % 0.013019 <.0001 0.1038 
0.0002 
20 
Number of positive 
antibodies class2(0-1, 
≥2) 
0.0631 0.6815 0.0011 15 
Number of positive 
antibodies class2(0-1, 
≥2) 
0.11663 0.4402 0.012294 <.0001 0.0983 0.0004 20 
Number of positive 
antibodies class3(0,1,2, 
≥3) 
0.2714 0.0247 0.2714 15 
0 0 0 
1 0.08 0.77 
2 0.276 0.258 
≥3 -0.00596 0.9799 
Number of positive 
antibodies class3(0,1,2, 
≥3) 
0.4976 BMI % 0.012220 0.0003 0.1089 0.0016 20 
0 0 0 
1 0.252 0.368 
2 0.347 0.144 
≥3 0.2086 0.3743 
Table 12 provided the statistical information about the univariate regression and 
univariate regression with BMI percentile adjustment of log (leptin).  
P-value: In the univariate regression analysis, ZnT8A and insulin dose were significant 
for predicting log (leptin). When age was added into the model, insulin dose was still significant 
but ZnT8A became non-significant.   
Table 12 Continued
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β coefficients: The β coefficient for insulin dose revealed positive linear relationship with 
log (leptin) when age was adjusted or not.  
R2 : The R2 was very small, demonstrating that the variation explained from insulin dose 
was very low(9.9%). When BMI percentile included in the model, the R2 increased to 17.6%.   
Covariate adjustment variable: BMI percentile was significant for predicting log (leptin) 
and had positive linear relationship with log (leptin).  
Table 13. Simple regression with C-peptide, glucose of log (leptin) 
Independent Var1 β P-value Independent Var2 β P-value R2 Pr > F N of 
missing 
Glucose -0.0017 0.054 0.025 27 
C-peptide 0.115 0.0053 0.05 22 
C-peptide/ glucose 18.65 0.0002 0.092 34 
C-peptide 0.11 0.0076 Glucose -0.002 0.07 0.07 0.0061 34 
C-peptide 0.12 0.004 Glucose(<120, >=120) -0.34 0.0114 0.09 0.0013 34 
Table 13 provided the results of simple regression with C-peptide and glucose of log 
(leptin).  
P-value: All the predictors of glucose and C-peptide were significant for predicting log 
(leptin).   
β coefficients: The β coefficient of glucose showed a negative linear relationship between 
glucose and log (leptin).  The β coefficients of other variables were all positive, revealing the 
positive linear relationship between the other variables and log (leptin).  
R2: The R2 were very small, from 2% to 9%.  
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3.4.3 Simple regression of log(adiponectin/leptin) 
Table 14. Univariate regression and univariate regression with age adjustment of log (adiponectin/leptin) 
Independent Var Β P-value Adjusted Var β P-value R2 Pr > F N of 
missing 
BMI % -0.0123 0.0013 0.06576 20 
BMI % -0.0121 0.0007 Age -0.0077 <.0001 0.19177 <.0001 20 
BMI z-score -0.4163 <.0001 0.10385 20 
BMI z-score -0.4137 <.0001 Age -0.0077 <.0001 0.22991 <.0001 20 
Central obesity -0.7005 0.0002 0.10454 44 
Central obesity -0.6795 0.0001 Age -0.0071 <.0001 0.21373 <.0001 44 
Waist -0.0324 <.0001 0.19948 41 
Waist -0.0298 0.0003 Age -0.0011 0.6373 0.20085 <.0001 41 
Height -0.0139 <.0001 0.10894 18 
Height 0.00176 0.8614 Age -0.0083 0.1015 0.12438 <.0001 18 
Waist/height -4.5058 0.001 0.08115 44 
Waist/height -4.9918 0.0001 Age -0.0078 <.0001 0.21432 <.0001 44 
HbA1c 0.00293 0.9758 6E-06 23 
HbA1c -0.1358 0.1525 Age -0.008 <.0001 0.13293 <.0001 23 
Cholesterol 0.00109 0.6854 0.00108 21 
Cholesterol -0.0007 0.7895 Age -0.0076 <.0001 0.1255 <.0001 21 
LDL -0.0068 0.0624 0.03892 85 
LDL -0.0058 0.0752 Age -0.01 <.0001 0.24045 <.0001 85 
HDL 0.00478 0.4801 0.00329 21 
HDL 0.00012 0.9848 Age -0.0076 <.0001 0.12509 <.0001 21 
DQ2/DQ8  0.9149 0.0033 0.9149 15 
X 0 0 
DQ2 -0.1552 0.506 
DQ2/DQ8 class -0.044 0.859 
DQ8 -0.0566 0.7988 
DQ2/DQ8  0.9765 Age -0.0073 <.0001 0.1256 0.0003 15 
X 0 0 
DQ2 -0.09 0.68 
DQ2/DQ8 class -0.045 0.85 
DQ8 -0.02316 0.9117 
Triglycerides 0.00063 0.6648 0.00124 21 
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Triglycerides 7.5E-06 0.9957 Age -0.0076 <.0001 0.12508 <.0001 21 
Percentile for diastolic 
blood pressure 
0.00347 0.3852 0.00572 41 
Percentile for diastolic 
blood pressure 
-0.0038 0.3762 Age -0.0071 0.0003 0.10112 0.0009 41 
Percentile for systolic 
blood pressure 
0.00165 0.5944 0.00215 41 
Percentile for systolic 
blood pressure 
-0.002 0.5218 Age -0.0067 0.0003 0.09855 0.0011 41 
Table 14 provided the results of the univariate regression and univariate regression with 
age adjustment of log (adiponectin/leptin).  
P-value: In the univariate regression, BMI percentile, BMI z-score, central obesity, waist, 
height and waist/height ratios were significant for predicting log (adiponectin/leptin). When age 
was added into the model, those variables were still significant except height, due to the high 
correlation between age and height.  
β coefficients: The β coefficients of BMI percentile, BMI z-score , central obesity, waist, 
height and waist/height ratios in univariate regression models were negative, revealing a negative 
linear relationship between those variables and log (adiponectin/leptin).  
R2: In the univariate analysis, the R2 indicated that the variation explained from those 
variables were from 6% to 20%. After the addition of age into the model, the percent of variation 
explained in the dependent variable increased from 20% to 23%.   
Covariate adjustment variable: Age was significant for predicting log 
(adiponectin/leptin). However, with the addition of waist and height, age became non-significant 
because of high correlations between age and height and age and waist. Age had negative linear 
relationship with log (adiponectin/leptin), indicating that when age increased, log 
(adiponectin/leptin) decreased.  
Table 14 Continued
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Table 15. Univariate regression and univariate regression with BMI percentile adjustment of log 
(adiponectin/leptin) 
Independent Var β P-value Adjusted Var β P-value R2 Pr > F 
N of 
missing 
IA2 0.116 0.4092 0.00432 15 
IA2 0.03527 0.8058 BMI % -0.0121 0.0019 0.06614 0.0055 20 
IAA 0.00751 0.9386 0.00013 125 
IAA -0.0039 0.9668 BMI % -0.0179 0.0082 0.14255 0.0291 126 
ICA 0.00447 0.4003 0.00448 15 
ICA 0.0046 0.3816 BMI % -0.0123 0.0012 0.07047 0.0039 20 
GAD -0.0878 0.7261 0.00078 15 
GAD -0.3143 0.2218 BMI % -0.0134 0.0006 0.07492 0.0027 20 
ZnT8A 0.47839 0.1107 0.01687 23 
ZnT8A 0.32146 0.2929 BMI % -0.0127 0.0018 0.08359 0.0019 28 
Zinc category (+  ,-) -0.0656 0.7259 0.00096 44 
Zinc category (+  ,-) -0.1842 0.3258 BMI % -0.0165 0.0003 0.10061 0.0014 48 
Insulin dose -0.9383 0.0007 0.07551 27 
Insulin dose -0.8274 0.0027 BMI % -0.011 0.0036 0.12854 <.0001 30 
Number of positive 
antibodies 
0.6149 0.0170 0.6149 15 
0 0 0 
1 0.1286 0.697 
2 -0.243 0.4 
3 -0.103 0.72 
4 -0.218629 0.5574 
Number of positive 
antibodies 
0.6492 BMI % -0.0127 0.0019 0.0811 0.0262 20 
0 0 0 
1 -0.09 0.789 
2 -0.32 0.268 
3 -0.334 0.254 
4 -0.4 0.2806 
Number of positive 
antibodies (continuous) 
-0.058 0.42 0.004 15 
Number of positive 
antibodies (continuous) 
-0.104 0.15 BMI % -0.0132 0.0006 0.0785 0.002 20 
Number of positive -0.128 0.6352 0.0014 0.6532 15 
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antibodies class1(0, ≥1) 
Number of positive 
antibodies class1(0, ≥1) 
-0.307436 0.2564 BMI % -0.013 0.0007 0.0737 0.0030 20 
Number of positive 
antibodies class2(0-1, 
≥2) 
-0.2523 0.1664 0.0121 0.1664 15 
Number of positive 
antibodies class2(0-1, 
≥2) 
-0.282 0.1249 BMI % -0.012342 0.0011 0.0802 0.0017 20 
Number of positive 
antibodies class3(0,1,2, 
≥3) 
0.4715 0.0160 0.4715 15 
0 0 0 
1 0.129 0.697 
2 -0.243 0.403 
≥3 -0.123637 0.6608 
Number of positive 
antibodies class3(0,1,2, 
≥3) 
0.4882 BMI % -0.01273 0.0017 0.0807 0.0128 20 
0 -0.093 0.786 
1 -0.32 0.266 
2 -0.32 0.266 
≥3 -0.347 0.2258 
Table 15 provided the results of the univariate regression and univariate regression with 
BMI percentile adjustment of log (adiponectin/leptin).  
P-value: In the univariate regression analysis, only insulin dose was significant for 
predicting log (adiponectin/leptin). After age was adjusted, insulin dose was still significant. 
β coefficients: The β coefficient  of insulin dose in univariate regression model  was 
negative, revealing the negative linear relationship between insulin dose and log 
(adiponectin/leptin).  
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R2: The R2 was small, demonstrating that the variation explanation from insulin dose was 
7.5%. When BMI percentile was added into the model, the effect of predicting variation of 
insulin dose increased to 12.8%.   
Covariate adjustment variable: BMI percentile was significant for predicting log 
(adiponectin/leptin) and had a negative linear relationship with log (adiponectin/leptin).  
Table 16. Simple regression with C-peptide, glucose of log (adiponectin/leptin) 
Table 16 provided the results of simple regression with C-peptide and glucose of log 
(adiponectin/leptin).  
P-value: All of the glucose and C-peptide variables were significant predictors of log 
(adiponectin/leptin).   
β coefficients: Glucose had a positive β coefficient, revealing the positive linear 
relationship between glucose and log (adiponectin/leptin). The β coefficients of the other 
predictors were all negative, revealing a negative relationship with log (adiponectin/leptin). 
R2: The R2 were very small, from 2% to 10%.  
3.4.4 Comparison of univariate regression results 
From Table 17, summarized the result of the univariate regression models 
Independent Var1 β p-value Independent Var2 β p-value R2 Pr > F 
N of 
missing 
Glucose 0.002 0.0562 0.02475 27 
C-peptide -0.1251 0.0107 0.04233 22 
C-peptide/ glucose -22.252 0.0002 0.09371 34 
C-peptide -0.1251 0.0111 Glucose 0.00196 0.0581 0.06896 0.0072 34 
C-peptide -0.1353 0.0059 Glucose(<120, >=120) 0.38423 0.0153 0.084 0.0023 34 
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Number of positive antibodies classes:  For log (leptin) and log (adiponectin/leptin), the 
number of positive antibody level was not significant as a predictor. When the outcome variable 
was log (adiponectin), the number of positive antibody level was significant. The β coefficient 
was negative, which revealed when the number of positive antibodies level increased, log 
(adiponectin) decreased.  
Waist, height and waist/height ratio: All the three variables were significant predictors for 
the three outcomes. For log (leptin), waist, height and waist/height had positive β coefficients. 
For log (adiponectin) and log (adiponectin/leptin), waist, height and waist/height had negative β 
coefficients.  
The remaining variables:  The remaining variables were significant only for log (leptin) 
and log (adiponectin/leptin) and their associations were in opposite directions as indicated by 
sign of the β coefficients. 
Table 17. Comparison of univariate regression results 
Significant predictor 
β coefficient sign for 
log(adiponectin) 
β coefficient sign for 
log(leptin) 
β coefficient sign for 
log(adiponectin/leptin) 
Waist ─ ┼ ─ 
Height ─ ┼ ─ 
Waist/height ─ ┼ ─ 
Number of positive antibodies (continuous) ─ Not significant Not significant 
Number of positive antibodies class2(0-1, ≥2) ─ Not significant Not significant 
Number of positive antibodies class3(0,1,2, ≥3) ─ Not significant Not significant 
BMI % Not significant ┼ ─ 
BMI z score Not significant ┼ ─ 
Central obesity Not significant ┼ ─ 
ZnT8A Not significant ─ Not significant 
Insulin dose Not significant ┼ ─ 
Glucose Not significant ─ ┼ 
C-peptide Not significant ┼ ─ 
C-peptide/ glucose Not significant ┼ ─ 
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3.5 MULTIVARIATE LINEAR REGRESSION 
3.5.1 Independent variables selection procedures for multivariate regression models        
To select the independent variables of the multivariate regression models, two selection 
procedures were performed in parallel and compared: manual, and a combination automatic + 
manual selection procedure. All multivariate regression models were fit using PROC GLM in 
SAS 9.3. 
Manual selection procedure:    
An initial model was run including all non-correlated variables and one variable from 
each of the five highly correlated groups (Table 7). Each of the variables from the five highly 
correlated groups was chosen randomly for inclusion in the initial model.  This approach was 
designed to decrease collinearity resulting from inclusion of more than one variable from a given 
highly correlated group. For example, in the highly correlated group 1, BMI percentile was used 
as a first candidate and the other variables in group 1 were left out. All other non-correlated 
variables which did not belong to the highly correlated groups were added into the initial model 
simultaneously.         
Individual predictors in the initial model were considered for exclusion if p-value >0.05, 
except for BMI percentile in the log(adiponectin) model as this specific relationship was of 
interest. The individual variable associated with the highest p-value was then excluded, and the 
model with remaining variables was refit in the next iteration, and the process was repeated as 
long as the removal of a specific variable did not reverse the significance of variables remaining 
in the model. For example, if one predictor was excluded with other previously significant 
variables changed to be nonsignificant, then the variable should be kept in the model. 
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If some of the remaining variables in the fitted model were chosen from highly correlated 
groups, other variables in the same groups were substituted into the model and the results were 
compared. The variable was kept in the model if it had lowest individual p-value compared to the 
other variables in the same highly correlated group. The final model was that which included any 
variables significant at the 0.05 level following this selection procedure, as well as the most 
significant highly correlated variable within a group. For example, if LDL was tested to be 
significant, cholesterol would also have been tested in a separate model with the other previously 
selected variables (based on the p<0.05 criterion). If the model including cholesterol had lower 
p-value compared to the model including LDL (cholesterol and LDL were in the same highly 
correlated variable group), then cholesterol would be selected instead of LDL in the final model.  
Automatic + Manual selection procedure:  
For this alternative variable selection approach, the independent variables of the initial 
model included all non-correlated variables and one variable from each of the five highly 
correlated groups, similar to the manual selection procedure. However, a preliminary round of 
variable selection was performed by SAS automatically using a stepwise selection criteria 
(slentry=0.25 slstay=0.15 in SAS code). Once the procedure was completed, the selection was 
modified manually. For example, if some of the selected predictors were chosen from correlated 
groups, other variables in the same groups were later substituted for them and the model was 
refit, similar to the process described above. And using the same manual selection procedure, the 
variable in the highly correlated group was kept in the model if it had lowest individual p-value. 
In addition, if the automatic procedure removed BMI percentile in the log(adiponectin) model, 
then it would be added back (as this specific relationship between BMI percentile and 
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log(adiponectin) was of interest). The resulting model after applying this selection protocol was 
deemed the final model.     
3.5.2 Final models of log (adiponectin) 
Table 18. Multivariate linear regression models of log (adiponectin) 
Model Predictors 
β 
coefficient 
DF 
p-
value(overall/in
dividual) 
N of 
predi
ctors 
N of 
observati
ons 
Root 
MSE 
R2 
Adjust
ed R2 
AIC BIC 
1 
0.0003 
6 139 0.496 0.21 0.154 -44.55 -182 
BMI % 0.0026 1 0.3466 
Age -0.0024 1 0.0159 
Waist % 
<25% -* 
2 0.0006 25%-75% 0.067 
>75% -0.466 
Gender 0.1288 1 0.1579 
Number of positive antibodies 
class2(0-1,≥2) 
-0.28 1 0.0063 
DQ2/DQ8 
X - 
3 0.1920 
DQ2 0.115 
DQ2/DQ8 0.027 
DQ8 0.234 
2 
0.0005 
6 139 0.498 0.20 0.145 -43.07 -181 
BMI % 0.0014 1 0.5990 
Age -0.0022 1 0.0278 
Waist % 
<25% - 
2 0.0007 25%-75% 0.077 
>75% -0.457 
BMI % 0.1099 1 0.2277 
Number of positive antibodies 
Class3(0,1,2, ≥3) 
-0.1118 1 0.0134 
DQ2/DQ8 
X - 
3 0.2180 
DQ2 0.098 
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DQ2/DQ8 0.028 
DQ8 0.227 
3 
0.0017 
6 139 0.5 0.21 0.14 -39.21 
-
175.5
5 
BMI % 0.00254 1 0.3832 
Age -0.0024 1 0.0184 
Waist % 
<25% - 
2 0.0010 25%-75% 0.063 
>75% -0.46 
Gender 0.12271 1 0.1974 
Number of 
positive 
antibodies 
0 - 
4 0.0918 
1 0.0999 
2 -0.187 
3 -0.242 
4 -0.19 
DQ2/DQ8 
X - 
3 0.2145 
DQ2 0.1048 
DQ2/DQ8 0.0252 
DQ8 0.2287 
4 
0.0007 
6 139 0.497 
0.19
6 
0.14 -42.3 
-
179.7 
BMI % 0.00144 1 0.605 
Age -0.0022 1 0.032 
Waist % 
<25% - 
2 0.0007 
25%-75% 0.081 
>75% 
-
0.45 
Gender 0.098 1 0.282 
Number of positive antibodies 
(continuous) 
-0.095 1 0.0206 
DQ2/DQ8 
X - 
3 0.2274 
DQ2 0.092 
DQ2/DQ8 0.0265 
DQ8 0.224 
5 
<.0001 
3 144 0.497 0.17 0.14 -50.6 
-
194.2
4 
age -0.0026 1 0.0063 
Waist % 
<25% - 
2 0.0008 
25%-75% 0.142 
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>75% -0.331 
Number of positive antibodies 
class2(0-1,≥2) 
-0.2852 1 0.0040 
*Reference group
Five final models of log (adiponectin) were presented in Table 18.  
Models 1 to 4 indicated the consistent result with the previous univariate regression 
result.  
Model 1: 
P-value:  The results of univariate regression (Table 8) indicated number of positive 
antibodies class2 had the p-value of 0.0273.After adding BMI percentile, the p-value was 0.0585, 
close to the significant level of 0.05. And the results of multivariate regression model 1showed 
the p-value for number of positive antibodies class2 was 0.0063 when the other variables 
(including BMI percentile) were included.   
Model 2:  
P-value:  The results of univariate regression indicated number of positive antibodies 
class3 had the p-value of 0.057, close to the significant level of 0.05. After BMI percentile was 
included in the model, the p-value was 0.1472. And the results of multivariate regression model 
2 showed the p-value of number of positive antibodies class3 was 0.0134 when the other 
variables (including BMI percentile) were included.      
Model 3: 
P-value:  When number of positive antibodies was treated as a categorical variable and 
when BMI percentile was adjusted, in both the multivariate and univariate regression models, 
number of positive antibodies was not significant for predicting log (adiponectin).  
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Model 4: 
P-value:  In the univariate regression, when number of positive antibodies was treated as 
a continuous variable, it was a significant predictor of log (adiponectin), with a p-value of 
0.0421. The p-value increased to 0.0538 after BMI percentile was adjusted. And in the 
multivariate regression model 4, it was also significant with a p-value of 0.0206 when  other 
variables (including BMI percentile) were included.  
Models 1 to 4:  
β coefficients : The β coefficients for the number of positive antibodies classes was 
negative, indicating that subjects with a greater number of positive antibodies had higher log 
(adiponectin) level.  
Waist percentile and age were also significant for predicting log (adiponectin). There was 
a negative linear relationship between age and log (adiponectin). Individuals in the highest waist 
percentile group (>75%) had lower log (adiponectin) levels and those in the 25-75% group had 
higher log (adiponectin) levels compared to individuals in the lowest waist group(<25%). 
Model 5: 
Mean squared error root (MSE root), R2 Adjusted R2, Akaike information criterion (AIC) 
and Bayesian information criterion (BIC) of the five models were also presented in Table 18.  
The five models had similar MSE root, R2, adjusted R2, AIC and BIC values. Model 5 
was selected by the stepwise criteria in SAS and had the smallest AIC and BIC and did not 
include BMI percentile. The other four models helped to reveal a relationship of interest between 
number of positive antibodies and log (adiponectin) when the other variables (including BMI 
percentile) were included. 
39 
3.5.3 Final models of log (leptin) 
Table 19.  Multivariate linear regression models of log (leptin) 
Model Predictors 
Beta 
coefficient 
DF 
p-
value(overall/in
dividual) 
N of 
predi
ctors 
N of 
observati
ons 
Root 
MSE 
R2 
Adju
sted 
R2 
AIC BIC 
6  
<.0001 
10 122 0.61 0.49 0.44 15.48 -103.4 
BMI z-score 0.478 1 <.0001 
C-peptide 0.1156 1 0.0037 
Age 0.0024 1 0.1071 
Gender 0.616 1 <0.0001 
DQ2/DQ8  
X - 
3 0.3439 
DQ2 0.121 
DQ2/DQ8 0.298 
DQ8 0.231 
Insulin dose 0.369 1 0.1008 
HbA1c  0.199 1 0.0169 
Glucose -0.0011 1 0.189 
ICA -0.0057 1 0.1133 
GAD 0.4639 1 0.02 
7 
<.0001 
6 106 0.63 0.48  0.45  15.96  -89.05  
BMI z-score 0.3294 1 0.0016 
C-peptide  0.10987 1 0.0059 
Central obesity 0.38531 1 0.0331 
Gender 0.54905 1 <.0001 
Glucose -0.0012 1 0.1735 
Insulin dose adjusted by HbA1c 0.16144 1 0.0002 
Two models were presented in Table 19. 
The final two models of log (leptin) revealed that number of positive antibody was not 
significant for predicting log (leptin).   
In model 6, BMI z-score, C-peptide, gender, HbA1c, and GAD were significant. All 
these variables had a positive linear relationship with log (leptin). In model 7, BMI z-score, C-
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peptide, central obesity, gender, and insulin dose adjusted by HbA1c were significant for 
predicting log (leptin) and all these variables had a positive linear relationship with log (leptin). 
Model 6 and 7 had similar predictors. The two models had similar findings with the univariate 
regressions (Table 17).   
Comparing the AIC, BIC, R2 and adjusted R2 of the two models, model 6 and 7 had 
similar AIC, R2 and adjusted R2 except BIC. The smaller number of observations might be a 
reason for the larger BIC of model 7. However, the two models showed similar significant 
predictors for predicting log (leptin). 
3.5.4 Final models of log (adiponectin/leptin) 
Table 20. Multivariate linear regression models of log (adiponectin/leptin)
Model Predictors 
Beta 
coefficient 
DF 
p-
value(overall/
individual) 
Number 
of 
predicto
rs 
Number of 
observatio
ns 
Root 
MSE 
R2 
Adjuste
d R2 
AIC BIC 
8 
<.0001 
5 115 0.78 0.4 0.367 66.36 -47.74 
BMI z-score -0.228 1 0.1067 
Insulin dose adjusted by HbA1c -0.137 1 0.0046 
Gender -0.407 1 0.0073 
Age -0.0074 1 <.0001 
Waist % 
<25% - 
2 0.0017 25%-75% 0.07 
>75% -0.953 
9 
HbA1c -0.3288 1 0.0048 
6 111 0.83 0.33 0.2884 78.08  -31.99 
Glucose 0.00273 1 0.0147 
C-peptide -0.1216 1 0.0191 
Waist/height -4.3144 1 0.0256 
Gender -0.455 1 0.0073 
BMI z-score -0.2487 1 0.1093 
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Two models were identified for log (adiponectin/leptin) and shown in Table 20. The final 
two models indicated that number of positive antibody was not a significant predictor of log 
(adiponectin/leptin). 
In model 8, insulin dose adjusted by HbA1c, gender, age and waist percentile were 
significant and all these variables except waist percentile had a negative linear relationship with 
log (adiponectin/leptin). Individuals in the highest waist percentile group (>75%) had lower log 
(adiponectin/leptin) levels and those in the 25-75% group had higher log (adiponectin/leptin) 
levels compared to individuals in the lowest waist group (<25%). In model 9, HbA1c, glucose, 
C-peptide, waist/height and gender were significant for predicting log (adiponectin/leptin) and 
only glucose had a positive linear relationship with log (adiponectin/leptin).   
Comparing the AIC, BIC, R2 and adjusted R2 of the two models, model 8 had higher R2, 
higher adjusted R2, smaller MSE root and smaller AIC and BIC. This indicated that model 8 fit 
better. The two models showed similar significant independent variables for predicting log 
(adiponectin/leptin).   
3.5.5 Results of multivariate regression models 
The final multivariate regression models gave consistent results with the univariate 
regression results (Table 17). For log (adiponectin), waist percentile, number of positive 
antibodies and age were significant predictors. When number of positive antibodies or age 
increased, log (adiponectin) level decreased. Individuals in the highest waist percentile group 
(>75%) had lower log (adiponectin) levels and those in the 25-75% group had higher log 
(adiponectin) levels compared to individuals in the lowest waist group (<25%). For log (leptin), 
BMI z-score, C-peptide, gender, HbA1c, central obesity, gender, and insulin dose adjusted by 
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HbA1c were significant predictors. For log (adiponectin/leptin), the significant predictors were 
gender, age, waist percentile, HbA1c, glucose, C-peptide and waist/height ratio.  
3.6  TEST OF REGRESSION MODEL ASSUMPTIONS 
3.6.1 Existence 
For each specific combination of the predictors, log (adiponectin), log (leptin) and log 
(adiponectin/leptin) had normal distributions, according to Figure 1 and Table 2.   
3.6.2 Independence 
Log (adiponectin), log (leptin) and log (adiponectin/leptin) were randomly distributed. 
3.6.3 Linearity 
The partial regression plot of residuals versus each predictor with adjustment for all other 
predictors indicated if any nonlinearity was present in the relationship between outcome variable 
and each predictor. For log (adiponectin), log (leptin) and log (adiponectin/leptin), those plots 
between continuous predictors and the outcomes did not indicate a clear departure from linearity. 
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3.6.3.1 Linearity testing for log (adiponectin) 
The partial regression plots generally showed a linear relationship between the 
continuous predictors and the log (adiponectin). However there was variability as indicated by a 
noticeable amount of scatter around the regression line. (Figure 2 to 6).  
Figure 2. Partial regression residual plot for model 1 
Figure 3. Partial regression residual plot for model 2 
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Figure 4. Partial regression residual plot for model 3 
Figure 5. Partial regression residual plot for model 4 
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Figure 6. Partial regression residual plot for model 5 
3.6.3.2 Linearity testing for log (leptin) 
The partial regression plots generally showed a linear relationship between the 
continuous predictors and the log (leptin). However there was variability as indicated by a 
noticeable amount of scatter around the regression line. (Figure 7 to 8).   
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Figure 7. Partial regression residual plot for model 6 
Figure 8. Partial regression residual plot for model 7 
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3.6.3.3 Linearity testing for log (adiponectin/leptin) 
The partial regression plots generally showed a linear relationship between the 
continuous predictors and the log (adiponectin/leptin). However there was variability as 
indicated by a noticeable amount of scatter around the regression line. (Figure 9 to 10). 
Figure 9. Partial regression residual plot for model 8 
Figure 10. Partial regression residual plot for model 9 
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3.6.4 Homoscedasticity 
The homoscedasticity could be tested by looking if the variance of outcome variables 
were the same for any fixed combination of predictors. The two dimensional plots could help to 
test the homoscedaticity problem.  
There were two plots corresponding to each model. The first was plot between the 
residuals and the predicted outcomes. If the pattern was randomly distributed, the 
homoscedasticity assumption was fulfilled. The second plot was between the outcomes and the 
predicted outcomes. If a linear relationship was displayed, then the homoscedasticity assumption 
was fulfilled.   
From the following plots (Figure 12, Figure 14, Figure 16, Figure 18, Figure 20, 
Figure 22, Figure 24, Figure 26, Figure 28) of all nine models, the residuals were all randomly 
distributed versus the predicted outcomes. The positive linear relationships between the 
outcomes and the predicted outcomes were clearly displayed from the scatter plots of outcomes 
versus predicted outcomes of model 1 to 9(Figure 11, Figure 13, Figure 15, Figure 17, Figure 
19, Figure 21, Figure 23, Figure 25, Figure 27).  
Figure 11. Model 1: Scatter plot of standardized residuals versus fitted points 
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Figure 12. Model 1: Scatter plot of outcome variables versus fitted points 
Figure 13. Model 2: Scatter plot of standardized residuals versus fitted points 
Figure 14. Model 2: Scatter plot of outcome variables versus fitted points 
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Figure 15. Model 3: Scatter plot of standardized residuals versus fitted points 
Figure 16. Model 3: Scatter plot of outcome variables versus fitted points 
Figure 17. Model 4: Scatter plot of standardized residuals versus fitted points 
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Figure 18. Model 4: The scatter plot of outcome variables versus fitted points 
Figure 19. Model 5: Scatter plot of standardized residuals versus fitted points 
Figure 20. Model 5: Scatter plot of outcome variables versus fitted points 
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Figure 21. Model 6: Scatter plot of standardized residuals versus fitted points 
Figure 22. Model 6: Scatter plot of outcome variables versus fitted points 
Figure 23. Model 7: Scatter plot of standardized residuals versus fitted points 
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Figure 24.Model 7: Scatter plot of outcome variables versus fitted points 
Figure 25.Model 8: Scatter plot of standardized residuals versus fitted points 
Figure 26. Model 8: Scatter plot of outcome variables versus fitted points 
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Figure 27. Model 9: Scatter plot of standardized residuals versus fitted points 
Figure 28. Model 9: Scatter plot of outcome variables versus fitted points 
3.6.5 Normality 
For any fixed combination of predictors, the outcome variables had normal distributions. 
The normality could be tested by plotting the residuals. One dimensional histogram and the QQ 
plot could reveal the normality of the residuals and helped to test if the outcome variables had 
normal distributions.  
The histogram and QQ plots (Figure 29-37) of the residuals indicated that the residuals 
were normally distributed, comparing with the standard normal distribution. The p-values of 
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Goodness-of-Fit Tests for normal distribution by Kolmogorov-Smirnov tests were all greater 
than 0.25, the normality assumption of all nine models were satisfied. 
Figure 29. Histogram and QQ plot of standardized residual versus normal distributions for model 1 
Figure 30. Histogram and QQ plot of standardized residual versus normal distributions for model 2 
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Figure 31. Histogram and QQ plot of standardized residual versus normal distributions for model 3
Figure 32. Histogram and QQ plot of standardized residual versus normal distributions for model 4 
       Figure 33. Histogram and QQ plot of standardized residual versus normal distributions for model 5 
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      Figure 34. The histogram and QQ plot of standardized residual versus normal distributions based on 
model 6 
Figure 35. Histogram and QQ plot of standardized residual versus normal distributions for model 7 
Figure 36. Histogram and QQ plot of standardized residual versus normal distributions for model 8 
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      Figure 37. Histogram and QQ plot of standardized residual versus normal distributions for model 9 
3.6.6 Leverage and influence points diagnostics 
3.6.6.1 Leverage points 
The leverage points were outliers in the predictor space, it could be clarified by using the 
criteria hi>2(k+1)/n, where k= number of predictors in the model, n = observation numbers. The 
following plots (Figure 38) showed the leverage points labeled with patient numbers for all nine 
models. For model 3 and 5, there were more than 10 leverage points. For the other models, the 
leverage points were no more than 5, these observations should be checked to detect if there 
were some unusual records or tests. 
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Figure 38. Leverage versus outcome variables for models 1to 9 
3.6.6.2 Influential points 
Cook’s distance was a summary measure of actual influence, it helped to classify the 
problematic points. We used the criteria (Cook’D >4/n) to detect the problematic points.  
The following plots in Figure 39 revealed the influences labeled with patient numbers for 
all nine models. For each model, there were more than 5 influential points, these observations 
should be checked to detect if there were some unusual records or tests.   
61 
62 
Figure 39. Cook’s Distance versus outcome variables for models 1 to 9 
3.6.7 Collinearity  
The variance inflation factor (VIF) quantified the severity of multicollinearity in the 
regression analysis. It provided an index that measured how much the variance  of an estimated 
regression coefficient was increased because of collinearity. 
A rule of thumb was that if VIF > 10 then multicollinearity was high.  From the 
following Table 21 to 23, all those VIFs for the predictors in the final models were no more than 
2.3, which revealed that no collinearity problems existed.  
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Table 21.VIFs for models 1 to 5 
Vifs for models of Log(adiponectin) 
Model1 BMI % Age Waist% Gender 
Number of positive antibodies 
class2(0-1,≥2) 
DQ2/DQ8 
VIF 1.74 1.02 1.73  1.08  1.02 1.05  
Model2 BMI % Age Waist% Gender 
Number of positive antibodies 
class3 (0,1,2,≥3) 
DQ2/DQ8 
VIF 1.78 1.01  1.74 1.07  1.02  1.05  
Model3/4 BMI % Age Waist% Gender 
Number of positive antibodies( 
continuous) 
DQ2/DQ8 
VIF 1.78 1.01  1.74  1.07  1.03 1.05  
Model5 Age Waist% 
Number of 
positive 
antibodies 
class2(0-1,≥2) 
VIF 1.01 1 1.01 
Table 22.VIFs for models 6 to 7 
VIFs for models of Log(Leptin) 
Model1 BMI z-score C-peptide Age Gende
r 
Insulin 
Dose 
HbA1c Glucose ICA GAD DQ2/DQ8 
VIF 1.21 1.34 1.34 1.16  1.35 1.38  1.31 1.05 1.17  1.09  
Model2 BMI z- 
score 
C-peptide Central 
obesity 
Gende
r 
Glucose Insulin dose 
adjusted by HbA1c 
VIF 1.65 1.15  1.66 1.09  1.07 1.21  
Table 23.VIFs for model 8 to 9 
Vifs for models of Log(Adiponectin-leptin ratio) 
Model1 BMI z-score Insulin dose 
adjusted by 
HbA1c 
Gender Age Waist% 
VIF 2.17 1.03  1.03  1.01  2.18  
Model2 HbA1c Glucose C-peptide Waist/height Gender BMI z- score 
VIF 1.25 1.14  1.15  2.18  1.09 7 2.22  
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4.0  DISCUSSION AND CONCLUSION 
This study found that adiponectin had different significant predictors compared to leptin 
and adiponectin/leptin ratio. However, there were some factors in common. 
The number of positive antibodies was statistically significant only for predicting 
adiponectin. It was significant, irrespective of adjustment by BMI percentile (p<0.05). The β 
coefficient revealed those subjects with greater numbers of positive antibodies had lower 
adiponectin levels. Additionally, waist percentile and age were significant predictors of 
adiponectin. Age had a negative (inverse) linear relationship with adiponectin.  Individuals in the 
highest waist percentile group (>75%) had lower adiponectin levels and those in the 25-75% 
group had higher adiponectin levels compared to individuals in the lowest waist group (<25%). 
For leptin, BMI z-score, central obesity, C-peptide, gender, HbA1c, GAD, and insulin 
dose adjusted by HbA1c were significant. These predictors all had positive linear relationships 
with leptin.  
For adiponectin/leptin ratio, waist percentile, waist/height ratio, insulin dose adjusted by 
HbA1c, HbA1c, gender, age, glucose and C-peptide were significant predictors. All of these 
predictors had negative (inverse) linear relationships with adiponectin/leptin ratio.  Individuals in 
the highest waist percentile group (>75%) had lower adiponectin levels and those in the 25-75% 
group had higher adiponectin levels compared to individuals in the lowest waist group (<25%). 
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These results were different from the conclusion in our previously published study: those 
subjects with the greatest number of positive autoantibodies had higher adiponectin, lower leptin, 
and higher adiponectin/leptin ratios than those with lower numbers of positive antibodies.  A 
possible explanation may be that the subjects between the two studies were different: first, the 
previous study was conducted from 1990 to 2000 and the current study enrolled a more recent 
cohort from 2004 to 2008.  The subjects of our current study were heavier with a median BMI 
percentile of 78.4 [IRQ: 16.6 - 99.7] in contrast to subjects from the previous study with a 
median BMI percentile of 62.1 [IRQ: 44.2-78.1].  Second, the design of the former study 
matched individuals by race, age, gender, and year of diagnosis. In the current analysis, over 
94% were Caucasian and race was not considered as a predictor. The contrast in results between 
the two studies was reasonable considering the differences in the two study cohorts.  
To confirm the findings of this study, further exploration of the data is warranted 
including examining interactions among various factors.  In this data set there were a limited 
number of subjects with complete information for IAA and LDL. As a result, the regression 
models could not adequately evaluate the relationship with our outcome measures.  Further data 
collection and analysis including these two predictors should be considered. 
Public health Significance:   
Adiponectin, leptin and the ratio of adiponectin to leptin each demonstrated their own 
unique predictors within this population of T1 diabetic children. As cited earlier, adiponectin is a 
protein produced by adipocyte cells and possesses potent insulin sensitizing and anti-
inflammatory properties [16].  Adiponectin protects against development of T2D and 
atherosclerosis in animal models [17].  Also higher circulating levels of adiponectin are 
associated with a lower risk of T2D and coronary heart disease in prospective studies [18]. 
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Therefore, it is reasonable to investigate the correlates and predictors of adiponectin in this group 
of children with newly diagnosed T1D.  The number of positive antibodies was significantly 
related to the prediction of adiponectin with or without adjustment by BMI percentile. The 
regression coefficient indicated those subjects with greater number of positive antibodies had 
lower adiponectin levels. Moreover, waist percentile was also an important predictor and had an 
inverse linear relationship with adiponectin.  The identification of potential modifiable risk 
factors in children with this condition would be high priority. 
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APPENDIX: SAS PROGRAM FOR REGRESSIONS 
* for adiponectin;
* stepwise to find the multi variables;
proc glmselect data=a.natalie0529_01;  
class waist_cate Dq2_dq8_b central_obesity n_pos_ab4 ; 
model logadi= bmipct_3months bmiz_3months cpeptide_beckerlab_3months 
central_obesity waistht_ratio agemos_3months gender  
n_pos_ab4 Dq2_dq8_b  insulindose a1c_3months
cholesterol_heinz_lab_3months ldl hdl_heinz_lab_3months  
Waist_cate IDA_A1C_3months IDA_A1C_cate glucose 
triglyceride_heinz_lab_3months p_dbp_score p_sbp_score  
ica gad_3months ia2_3months /selection=stepwise slentry=0.25 slstay=0.15;  
run; 
*model1;
proc glm data=a.natalie0529_01; 
class waist_cate dq2_dq8_b; 
model logadi= bmipct_3months agemos_3months  waist_cate   gender  
pos_ab4_class2 dq2_dq8_b /solution ss3; 
run; 
proc glmselect data=a.natalie0529_01;  
class waist_cate dq2_dq8_b/ ref=first;  
model logadi= bmipct_3months agemos_3months  waist_cate   gender  
pos_ab4_class2 dq2_dq8_b / selection=none stop=none stats=all; 
run;  
*plots for model1;
proc glm data=a.natalie0529_01; 
class waist_cate dq2_dq8_b; 
model logadi= bmipct_3months agemos_3months  waist_cate   gender   
pos_ab4_class2 dq2_dq8_b /solution ss3; 
output out=a.adi1 
predicted=fit residual=resid  
rstudent=studentized_resid; 
run; 
data a.adi1_1; 
set a.adi1; 
standardized_residual=resid/0.48; 
run; 
ods graphics on; 
ods graphics off;  
proc univariate data=a.adi1_1 ; 
var standardized_residual; 
title " The histogram of standardized residual compared to normal for model1 
(logadi) "; 
histogram standardized_residual / normal(mu=0 sigma=1 color=red) ;run; 
proc univariate data=a.adi1_1 ; 
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var standardized_residual; 
title " The QQplot of standardized residual compared to normal for model1 
(logadi) "; 
qqplot standardized_residual/ normal(mu=0 sigma=1  color=red) ;run; 
proc sgplot data=a.adi1_1; 
title " scatter plot of standardized residual VS fitted points for model1 
(logadi)"; 
scatter x= fit y=standardized_residual; 
run; 
proc sgplot data=a.adi1_1; 
title " scatter plot of outcome variable VS fitted variable for model1 
(logadi)"; 
scatter x= fit y=logadi; 
run; 
*model2;
proc glmselect data=a.natalie0529_01;  
class waist_cate dq2_dq8_b/ref=first;  
model logadi= bmipct_3months agemos_3months  waist_cate   gender   
pos_ab4_class3 dq2_dq8_b / selection=none stop=none stats=all;run;   
proc glm data=a.natalie0529_01; 
class waist_cate dq2_dq8_b; 
model logadi= bmipct_3months agemos_3months  waist_cate   gender   
pos_ab4_class3 dq2_dq8_b /solution ss3; 
output out=a.adi2 
predicted=fit residual=resid   
rstudent=studentized_resid;run; 
data a.adi2_1; 
set a.adi2; 
standardized_residual=resid/0.48; 
run; 
ods graphics on; 
proc univariate data=a.adi2_1 ; 
var standardized_residual; 
title " The histogram of standardized residual compared to normal for model2 
(logadi) "; 
histogram standardized_residual / normal(mu=0 sigma=1 color=red) ;run; 
proc univariate data=a.adi2_1 ; 
var standardized_residual; 
title " The QQplot of standardized residual compared to normal for model2 
(logadi) "; 
qqplot standardized_residual/ normal(mu=0 sigma=1  color=red);run;  
proc sgplot data=a.adi2_1; 
title " scatter plot of standardized residual VS fitted points for model2 
(logadi)"; 
scatter x= fit y=standardized_residual;run; 
proc sgplot data=a.adi2_1; 
title " scatter plot of outcome variable VS fitted variable for model2 
(logadi)"; 
scatter x= fit y=logadi;run; 
proc glm data=a.natalie0529_01; 
class waist_cate dq2_dq8_b; 
model logadi= bmipct_3months agemos_3months  waist_cate   gender  
pos_ab4_class3 dq2_dq8_b /solution ss3; run; 
proc glmselect data=a.natalie0529_01;  
class waist_cate dq2_dq8_b;  
model logadi= bmipct_3months agemos_3months  waist_cate   gender  
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pos_ab4_class3 dq2_dq8_b / selection=none stop=none stats=all;run;  
* model 3; 
proc glm data=a.natalie0529_01; 
class waist_cate dq2_dq8_b n_pos_ab4; 
model logadi= bmipct_3months agemos_3months  waist_cate   gender   
n_pos_ab4 dq2_dq8_b /solution ss3; 
output out=a.adi3 
predicted=fit residual=resid   
rstudent=studentized_resid;run; 
proc univariate data=a.adi3 ; 
var resid; 
histogram resid / normal ;run; 
data a.adi3_1; 
set a.adi3; 
standardized_residual=resid/0.48; 
run; 
proc univariate data=a.adi3_1 ; 
var standardized_residual; 
title " The histogram of standardized residual compared to normal for model3 
(logadi) "; 
histogram standardized_residual / normal(mu=0 sigma=1 color=red) ;run; 
proc univariate data=a.adi3_1 ; 
var standardized_residual; 
title " The QQplot of standardized residual compared to normal for model3 
(logadi) "; 
qqplot standardized_residual/ normal(mu=0 sigma=1  color=red) ;run; 
proc sgplot data=a.adi3_1; 
title " scatter plot of standardized residual VS fitted points for model3 
(logadi)"; 
scatter x= fit y=standardized_residual;run; 
proc sgplot data=a.adi3_1; 
title " scatter plot of outcome variable VS fitted variable for model3 
(logadi)"; 
scatter x= fit y=logadi;run; 
proc glmselect data=a.natalie0529_01;  
class waist_cate dq2_dq8_b n_pos_ab4/ref=first;  
model logadi= bmipct_3months agemos_3months  waist_cate   gender   
n_pos_ab4 dq2_dq8_b / selection=none stop=none stats=all;run;  
* model 4;  
proc glmselect data=a.natalie0529_01;  
class waist_cate dq2_dq8_b /ref=first;  
model logadi= bmipct_3months agemos_3months  waist_cate   gender   
n_pos_ab4 dq2_dq8_b / selection=none stop=none stats=all;run;  
proc glm  data=a.natalie0529_01;  
 class waist_cate dq2_dq8_b  ;  
model logadi=  bmipct_3months agemos_3months  waist_cate   gender   
n_pos_ab4 dq2_dq8_b;run;  
proc glm data=a.natalie0529_01; 
class waist_cate dq2_dq8_b ; 
model logadi=  bmipct_3months agemos_3months  waist_cate   gender   
n_pos_ab4 dq2_dq8_b /solution ss3; 
output out=a.adi4 
predicted=fit residual=resid   
rstudent=studentized_resid;run; 
proc univariate data=a.adi4 ; 
var resid; 
histogram resid / normal ;run; 
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data a.adi4_1; 
set a.adi4; 
standardized_residual=resid/0.48; 
run; 
proc univariate data=a.adi4_1 ; 
var standardized_residual; 
title " The histogram of standardized residual compared to normal for model4 
(logadi) "; 
histogram standardized_residual / normal(mu=0 sigma=1 color=red) ;run; 
proc univariate data=a.adi4_1 ; 
var standardized_residual; 
title " The QQplot of standardized residual compared to normal for model4 
(logadi) "; 
qqplot standardized_residual/ normal(mu=0 sigma=1  color=red) ;run;  
proc sgplot data=a.adi4_1; 
title " scatter plot of standardized residual VS fitted points for model4 
(logadi)"; 
scatter x= fit y=standardized_residual; 
run; 
proc sgplot data=a.adi4_1; 
title " scatter plot of outcome variable VS fitted variable for model4 
(logadi)"; 
scatter x= fit y=logadi; 
run; 
proc glm data=a.natalie0529_01;  
class waist_cate Dq2_dq8_b n_pos_ab4; 
model logadi= bmipct_3months agemos_3months  waist_cate   gender   
n_pos_ab4 Dq2_dq8_b/solution ss3;  run; 
proc glmselect data=a.natalie0529_01;  
class waist_cate dq2_dq8_b n_pos_ab4;  
model logadi= bmipct_3months agemos_3months  waist_cate   gender   
n_pos_ab4 dq2_dq8_b / selection=none stop=none stats=all;run;  
*model 5;  
proc glmselect data=a.natalie0529_01; 
class waist_cate pos_ab4_class2/ref=first; 
model logadi= agemos_3months waist_cate pos_ab4_class2/ selection=none 
stop=none stats=all;run;   
proc glm data=a.natalie0529_01; 
class waist_cate ; 
model logadi= agemos_3months waist pos_ab4_class2/solution ss3 ; 
output out=a.adi5 
predicted=fit residual=resid   
rstudent=studentized_resid;run; 
proc univariate data=a.adi5 ; 
var resid; 
histogram resid / normal ;run; 
data a.adi5_1; 
set a.adi5; 
standardized_residual=resid/0.489;run; 
 
proc univariate data=a.adi5_1 ; 
var standardized_residual; 
title " The histogram of standardized residual compared to normal for model5 
(logadi) "; 
histogram standardized_residual / normal(mu=0 sigma=1 color=red) ;run; 
proc univariate data=a.adi5_1 ; 
var standardized_residual; 
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title " The QQplot of standardized residual compared to normal for model5 
(logadi) "; 
qqplot standardized_residual/ normal(mu=0 sigma=1  color=red) ;run; 
proc sgplot data=a.adi5_1; 
title " scatter plot of standardized residual VS fitted points for model5 
(logadi)"; 
scatter x= fit y=standardized_residual; 
run; 
proc sgplot data=a.adi5_1; 
title " scatter plot of outcome variable VS fitted variable for model5 
(logadi)"; 
scatter x= fit y=logadi; 
run; 
* test the linearity;  
proc glm data=a.natalie0529_01; 
class waist_cate dq2_dq8_b; 
model logadi= bmipct_3months agemos_3months  waist_cate   gender   
pos_ab4_class2 dq2_dq8_b /solution ss3 ; run; 
title " partial regression residual plot for model1(logadi)";  
proc reg data=a.natalie0529_01; 
model logadi= bmipct_3months agemos_3months  waist_cate1 waist_cate2 
waist_cate3 gender pos_ab4_class2  
Dq28_1 Dq28_2 Dq28_3 Dq28_4/ partial r influence ;  
id PID; 
run; 
title " partial regression residual plot for model2(logadi)";  
proc reg data=a.natalie0529_01; 
model logadi=bmipct_3months agemos_3months  waist_cate1 waist_cate2 
waist_cate3 gender pos_ab4_class3 
Dq28_1 Dq28_2 Dq28_3 Dq28_4/ partial;  
id PID; 
run; 
title " partial regression residual plot for model3(logadi)";  
proc reg data=a.natalie0529_01; 
model logadi= bmipct_3months agemos_3months  waist_cate1 waist_cate2 
waist_cate3 gender pos0 pos1 pos2 pos3 pos4 
Dq28_1 Dq28_2 Dq28_3 Dq28_4/ partial;  
id PID; 
run; 
title " partial regression residual plot for model4(logadi)";  
proc reg data=a.natalie0529_01; 
model logadi= bmipct_3months agemos_3months  waist_cate1 waist_cate2 
waist_cate3 gender  n_pos_ab4 
Dq28_1 Dq28_2 Dq28_3 Dq28_4/ partial;  
id PID; 
run; 
title " partial regression residual plot for model5(logadi)";  
proc reg data=a.natalie0529_01; 
model logadi=agemos_3months  waist_cate1 waist_cate2 waist_cate3     
pos_ab4_class2/ partial;  
run; 
* influencial points; 
* model 1; 
proc reg data=a.natalie0529_01; 
model logadi= bmipct_3months agemos_3months  waist_cate1 waist_cate2 
waist_cate3  gender  pos_ab4_class2 
Dq28_1 Dq28_2 Dq28_3 Dq28_4/ r influence ;  run; 
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ods graphics on; 
proc reg data=a.natalie0529_01; 
model logadi=bmipct_3months agemos_3months  waist_cate1 waist_cate2 
waist_cate3 gender  pos_ab4_class2 
Dq28_1 Dq28_2 Dq28_3 Dq28_4/ partial influence ;  
output out= a.infadi1 r=residual rstudent=sdr h=lev cookD= cook;  
run; 
data a.infadi1a; 
set a.infadi1; 
standardized_residual=residual/0.48; 
run; 
data a.infadi1_1; 
set a.infadi1a; 
if lev> 0.1295 then PID1=PID; 
else PID1=.; 
if standardized_residual>= 3 then PID2=PID;  
else PID2=.; 
if cook>= 0.029 then PID3=PID; 
else PID3=.; 
run; 
proc sgplot data=a.infadi1_1; 
title " model1(logadi)"; 
scatter x= logadi y=lev/ datalabel=PID1 ; 
format PID1 8.0;run; 
proc sgplot data=a.infadi1_1; 
title " model1(logadi)"; 
scatter x= logadi y=standardized_residual/ datalabel=PID2 ;format PID2 
8.0;run; 
proc sgplot data=a.infadi1_1;title " model1(logadi)"; 
scatter x= logadi y=cook/ datalabel=PID3 ;format PID3 8.0;run; 
* model 2; 
proc reg data=a.natalie0529_01; 
model logadi= bmipct_3months agemos_3months  waist_cate1 waist_cate2 
waist_cate3   gender  pos_ab4_class3 
Dq28_1 Dq28_2 Dq28_3 Dq28_4/ partial influence ;  
output out= a.infadi2 r=residual rstudent=sdr h=lev cookD= cook;  
run; 
data a.infadi2_1; 
set a.infadi2; 
if lev> 0.1295 then PID1=PID; 
else PID1=.; 
if sdr>= 3 then PID2=PID;  
else PID2=.; 
if cook>= 0.029 then PID3=PID; 
else PID3=.; 
run; 
proc sgplot data=a.infadi2_1; 
title " model2(logadi)"; 
scatter x= logadi y=lev/ datalabel=PID1 ; 
format PID1 8.0;run; 
proc sgplot data=a.infadi2_1; 
title " model2(logadi)"; 
scatter x= logadi y=sdr/ datalabel=PID2 ;format PID2 8.0;run; 
proc sgplot data=a.infadi2_1;title " model2(logadi)"; 
scatter x= logadi y=cook/ datalabel=PID3 ;format PID3 8.0;run; 
proc graphics on; 
* model 3;  
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proc reg data=a.natalie0529_01; 
model logadi= bmipct_3months agemos_3months  waist_cate1 waist_cate2 
waist_cate3   gender  pos0 pos1 pos2 pos3 pos4 
Dq28_1 Dq28_2 Dq28_3 Dq28_4/ partial influence ;  
output out= a.infadi3 r=residual rstudent=sdr h=lev cookD= cook;  
run; 
data a.infadi3_1; 
set a.infadi3; 
if lev> 0.1295 then PID1=PID; 
else PID1=.; 
if sdr>= 3 then PID2=PID;  
else PID2=.; 
if cook>= 0.029 then PID3=PID; 
else PID3=.; 
run; 
proc sgplot data=a.infadi3_1; 
title " model3(logadi)"; 
scatter x= logadi y=lev/ datalabel=PID1 ; 
format PID1 8.0;run; 
proc sgplot data=a.infadi3_1; 
title " model3(logadi)"; 
scatter x= logadi y=sdr/ datalabel=PID2 ;format PID2 8.0;run; 
proc sgplot data=a.infadi3_1;title " model3(logadi)"; 
scatter x= logadi y=cook/ datalabel=PID3 ;format PID3 8.0;run; 
* model 4;  
proc reg data=a.natalie0529_01; 
model logadi= bmipct_3months agemos_3months  waist_cate1 waist_cate2 
waist_cate3   gender  n_pos_ab4 
Dq28_1 Dq28_2 Dq28_3 Dq28_4/ partial influence ;  
output out= a.infadi3 r=residual rstudent=sdr h=lev cookD= cook;  
run; 
data a.infadi4_1; 
set a.infadi4; 
if lev> 0.1295 then PID1=PID; 
else PID1=.; 
if sdr>= 3 then PID2=PID;  
else PID2=.; 
if cook>= 0.029 then PID3=PID; 
else PID3=.; 
run; 
proc sgplot data=a.infadi4_1; 
title " model4(logadi)"; 
scatter x= logadi y=lev/ datalabel=PID1 ; 
format PID1 8.0;run; 
proc sgplot data=a.infadi4_1; 
title " model4(logadi)"; 
scatter x= logadi y=sdr/ datalabel=PID2 ;format PID2 8.0;run; 
proc sgplot data=a.infadi4_1;title " model4(logadi)"; 
scatter x= logadi y=cook/ datalabel=PID3 ;format PID3 8.0;run; 
 
* model 5;  
proc reg data=a.natalie0529_01; 
model logadi= agemos_3months  waist_cate1 waist_cate2 waist_cate3      
pos0 pos1 pos2 pos3 pos4/ partial influence vif;  
output out= a.infadi5 r=residual rstudent=sdr h=lev cookD= cook;  
run; 
data a.infadi5_1; 
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set a.infadi5; 
if lev> 0.1111 then PID1=PID; 
else PID1=.; 
if sdr>= 3 then PID2=PID;  
else PID2=.; 
if cook>= 0.0278 then PID3=PID; 
else PID3=.; 
run; 
proc sgplot data=a.infadi5_1; 
title " model5(logadi)"; 
scatter x= logadi y=lev/ datalabel=PID1 ; 
format PID1 8.0;run; 
proc sgplot data=a.infadi5_1; 
title " model5(logadi)"; 
scatter x= logadi y=sdr/ datalabel=PID2 ;format PID2 8.0;run; 
proc sgplot data=a.infadi5_1;title " model5(logadi)"; 
scatter x= logadi y=cook/ datalabel=PID3 ;format PID3 8.0;run; 
* vif ;  
* model1;  
proc reg data=a.natalie0529_01; 
model logadi=bmipct_3months agemos_3months  waist_cate  gender   
pos_ab4_class2 dq2_dq8_b/ vif;  run; 
* model2;  
proc reg data=a.natalie0529_01; 
model logadi= bmipct_3months agemos_3months  waist_cate  gender   
pos_ab4_class3 dq2_dq8_b/ vif;  run; 
* model3/4;  
proc reg data=a.natalie0529_01; 
model logadi= bmipct_3months agemos_3months  waist_cate  gender   
n_pos_ab4 dq2_dq8_b/ vif;  run; 
* model5;  
proc reg data=a.natalie0529_01; 
model logadi= agemos_3months waist_cate  
pos_ab4_class2/vif ;run; 
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